Synthesis, characterization and in vitro cytotoxic activities of new steroidal thiosemicarbazones and thiadiazolines by Živković, Marijana et al.
RSC Advances
PAPER
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
1/
18
/2
01
8 
6:
31
:4
8 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View IssueSynthesis, characaCenter for Chemistry, Institute of Chemistry
Belgrade, Studentski trg 12-16, P. O. Box 4
E-mail: nkrstic@chem.bg.ac.rs
bInstitute of Oncology and Radiology of Serbi
of Serbia
cFaculty of Sciences, University of Novi Sad
Republic of Serbia
dFaculty of Chemistry, University of Belgra
11001 Belgrade, Republic of Serbia
† Electronic supplementary information (
and crystallographic data in CIF or
10.1039/c6ra01516f
Cite this: RSC Adv., 2016, 6, 34312
Received 18th January 2016
Accepted 14th March 2016
DOI: 10.1039/c6ra01516f
www.rsc.org/advances
34312 | RSC Adv., 2016, 6, 34312–3433terization and in vitro cytotoxic
activities of new steroidal thiosemicarbazones and
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Dusˇan M. Sladic´d and Natalija M. Krstic´*a
A series of new steroidal mono- and bis(thiosemicarbazones) (2a–e and 3a–e) and corresponding mono-
and bis(1,3,4-thiadiazolines) (4a–e and 5a–e) was synthesized, characterized and evaluated for their
anticancer activity. Detailed NMR analysis of the mono- and bis(thiosemicarbazones) revealed the
presence of two stereoisomers (Z and E) with diﬀerent conﬁgurations in the hydrazone moiety at the C-
3 position, where the substituents on the C(3)]N double bond in the main isomers adopted the E
conﬁguration. The conﬁgurations at C-3 and C-17 in thiadiazolines 4a–e and 5a–e were deduced by
detailed NMR analysis as well as by the examination of Dreiding molecular models and X-ray analysis of
3-thiadiazoline 4a, which conﬁrmed the structure and absolute conﬁguration at C-3. The synthesized
compounds were tested against six cancer cell lines (HeLa, K562, MDA-MB-361, MDA-MB-453, LS174
and A549), the normal human cell line MRC-5 and peripheral blood mononuclear cells (PBMC) isolated
from healthy donors. The best activity was exhibited by 3-thiosemicarbazones 2a, 2b, 2c and 2e and
3,17-bis(thiadiazolines) 5a and 5d. Examination of the mechanisms of cytotoxicity on cervical
adenocarcinoma HeLa cells revealed the pro-apoptotic action of these compounds, which triggered
both extrinsic and intrinsic apoptotic pathways. These compounds also showed the ability to decrease
angiogenesis in vitro. In addition, 3,17-bis(thiadiazolines) 5a and 5d showed high selectivity in anticancer
activity against all the examined malignant cell lines. Compound 5a displayed prominent anticancer
potential. The tested compounds showed poor antimicrobial activity.Introduction
Modications of the steroid backbone that cause changes in its
physiological activity leading to the creation of new, biologically
active molecules have become one of the main objectives of
today's steroid chemistry. Transformations of the steroidal
skeleton involving the introduction of heteroatoms and
formation of heterocyclic moieties have received much atten-
tion in view of the diﬀerent and interesting biological activities
that have been demonstrated.1 As a result, diﬀerent studies of
modications of the steroidal A, B and D rings, including the, Technology and Metallurgy, University of
73, 11001 Belgrade, Republic of Serbia.
a, Pasterova 14, 11000 Belgrade, Republic
, Trg D. Obradovi´ca 3, 21000 Novi Sad,
de, Studentski trg 12-16, P. O. Box 158,
ESI) available. CCDC 1038059. For ESI
other electronic format see DOI:
3incorporation of heteroatoms or heterocyclic rings, have been
reported.2–13 Such systems enhanced the biological activities of
these molecules, giving rise to a variety of antiproliferative,
antimicrobial, anti-inammatory, hypotensive, hypocholester-
olemic and diuretic activities. On the other hand, substituted
thiosemicarbazone derivatives have attracted considerable
attention due to their interesting biological activity.14
Compounds containing a thiosemicarbazone moiety are known
to possess tranquilizing,15 muscle relaxing, psychoanaleptic,
hypnotic,16–19 antidepressant,20 antimicrobial,14,21,22 anti-
amoebic,23 analgesic, anti-inammatory24,25 and cytotoxic
activities.26 Also, thiosemicarbazones are important compounds
as possible ligands for metal complexes and for the synthesis of
heterocyclic compounds.27–35 Heterocyclic compounds, espe-
cially those containing S and N atoms, are of great importance
in treating biological systems.21 Among these, thiazole, thiazo-
lidinone, and thiadiazoline are of great signicance because
they constitute the structural frameworks of several naturally
occurring alkaloids that show a wide range of pharmaceutical
and industrial importance.35
Our interest in the transformation of steroidal compounds
has for quite some time been focused on modied steroids that
contain heteroatoms, new functional groups or heterocyclicThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinesystems as a part of their skeleton. Within this research area, we
have recently reported a few papers on the synthesis and bio-
logical activity of steroidal lactams, thiolactams, and several
sulfur- and sulfur and phosphorus-containing compounds,
including new steroidal dimers, 3-thiones, 3,17-dithiones, 1,2,4-
trithiolanes, and phosphorotrithioates, as well as 17-spiro- and
17-substituted-1,3,2-oxathiaphospholane-2-suldes.8,36–39
The results mentioned above prompted us to prepare new
modied A ring- and A and D ring-substituted derivatives from
3-oxo-a,b-unsaturated steroids. Here, we report the synthesis of
new mono- and bis(thiosemicarbazones) and mono- and
bis(1,3,4-thiadiazolines) derived from several androstene
derivatives (androst-4-ene-3,17-dione, 19-norandrost-4-ene-3,17-
dione, androsta-4,9(11)-diene-3,17-dione, 11a-hydroxyandrost-
4-ene-3,17-dione and pregn-4-ene-3,20-dione) and their biolog-
ical activity.
Steroidal thiosemicarbazones are well known and have been
prepared for many years, but still there are only a few studies
that provide detailed information on steroidal thio-
semicarbazone isomers and even fewer about 1,3,4-thiadiazo-
lines. For these reasons, we considered it important to
synthesize new examples and provide and discuss all their
structural details. The main focus of the chemistry section in
the present work is concentrated on detailed congurational
analysis, in particular the determination of the Z/E congura-
tion of the C(3)]N double bond in thiosemicarbazones and theFig. 1 Steroidal thiosemicarbazones and thiadiazolines with antibac-
terial activity.
This journal is © The Royal Society of Chemistry 2016absolute conguration at C(3) and C(17) in mono- and bis(1,3,4-
thiadiazolines), which was conrmed by X-ray analysis.
In addition, amongst the steroidal thiosemicarbazones and
thiadiazolines synthesized so far, a very small number of papers
deal with their biological activity and most of these studies
describe the antibacterial eﬀect of such compounds (I–VIII)
(Fig. 1),14,21,40–43 whereas only a few studies have been carried out
on steroidal thiosemicarbazones and thiadiazolines as anti-
tumor agents (IX–XV) (Fig. 2).44–49
In a similar way, another goal of this work was to perform an
extensive investigation of the in vitro cytotoxic activity of the
newly synthesized steroid derivatives. These compounds were
tested against six human malignant cell lines: cervical adeno-
carcinoma (HeLa), two breast cancer cell lines (MDA-MB-453
and MDA-MB-361), chronic myelogenous leukemia (K562),
colon adenocarcinoma (LS174) and lung adenocarcinoma
(A549) cells.
Also, their cytotoxic activity was tested against normal
human lung broblasts MRC-5. Compounds that exerted the
most pronounced cytotoxic action were further screened for
cytotoxic activity against normal human peripheral blood
mononuclear cells (PBMC), which were non-stimulated and
stimulated to proliferate with the mitogen phytohaemag-
glutinin (PHA). The specic aim of the study in this respect was
to get an insight into the mechanisms of the cytotoxic eﬀects of
the tested compounds.Fig. 2 Steroidal thiosemicarbazones and thiadiazolines as cytotoxic
agents.
RSC Adv., 2016, 6, 34312–34333 | 34313
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View Article OnlineResults and discussion
Chemistry
Steroidal thiosemicarbazones 2a–e and 3a–e were prepared
starting from steroids 1a–e and thiosemicarbazide in EtOH in
the presence of CH3COOH. The reaction was conducted until
complete consumption of 1a–e occurred, leading to thio-
semicarbazones 2a–e and 3a–e. Compounds 2a–e with a 3-thio-
semicarbazone group were obtained by ensuring an equimolar
ratio of 1a–e to thiosemicarbazide (1 : 1), because the a,b-
unsaturated 3-carbonyl group was more active than the 17-
carbonyl in 1a–d and the 20-carbonyl in 1e, and thio-
semicarbazide selectively reacted with the 3-carbonyl. However,
even under such conditions bis(thiosemicarbazones) 3a–e were
obtained in small amounts (6–13%). In order to synthesize
compounds 3a–e, the same reaction was performed with another
molar ratio of thiosemicarbazide to 1a–e (2 : 1), and under these
conditions bis(thiosemicarbazones) 3a–ewere obtained inmuch
higher yields (48–56%). In this reaction, the formation of 3-thi-
osemicarbazones 2a–e was observed as well and these products
were isolated in yields of 6–11% (Scheme 1). The thio-
semicarbazones were further subjected to ring closure by means
of acetylating agents21,39,50 to obtain the corresponding 1,3,4-Scheme 1 Synthesis of new steroidal thiosemicarbazones and thiadiazo
34314 | RSC Adv., 2016, 6, 34312–34333thiadiazolines 4a–e and 5a–e in good yields (56–73%) (Scheme
1). All compounds were characterized by their analytical and
spectroscopic data (HRMS, IR, 1DNMR, 2DNMR, HSQC, HMBC,
NOESY, and COSY), analysis by which enabled the complete 1H
and 13C assignment of each compound and its (E)- and (Z)-
isomers.
The 1H and 13C NMR analysis of compounds 2a–e and 3a–e
revealed the presence of two pairs of signals, which pointed to
the existence of two diastereoisomers, which, despite the fact
that the (E)-isomers were always obtained in excess (deduced by
comparing the peak areas of H-4 and H–N–N]C(3) in the cor-
responding 1H NMR spectra), could not be separated. All our
eﬀorts to separate the isomers by crystallization or by chroma-
tography on silica failed (no eluent that was tested caused
separation of the diastereoisomers). For that reason, all spectra
that were taken were of mixtures of 2a–e and 3a–e.
Spectral analysis demonstrated that the thiosemicarbazone
fragment of 2a was at the C-3 position and those of 3a at both C-
3 and C-17 positions. The existence of two isomers of both
compounds can be attributed to the hydrazonemoiety at the C-3
position, where the substituents on the C(3)]N double bond of
the main isomers adopted the E conguration.lines 2–5.
This journal is © The Royal Society of Chemistry 2016
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View Article OnlineThe molecular formula of 2a was deduced to be C19H27N3OS
from ESI-TOF-MS, which showed that the molecular weight of
2a was 73 Da higher than the molecular weight of the parent 19-
norandrost-4-ene-3,17-dione (1a), which conrmed that
compound 2a contained a thiosemicarbazone moiety.
In the IR spectrum of 2a, the absorption band for carbonyl at
C-3 wasmissing but the C(17)]O absorption band at 1732 cm1
was unchanged. In addition, new absorption bands at 1586 and
1497 cm1 appeared, which were attributed to n(C]N)
stretching vibrations, as well as additional sharp bands in the
region of 3246–3422 cm1, which were due to n(N–H) stretching
vibrations, and a strong band at 1284 cm1, which was ascribed
to n(C]S), which all conrmed the formation of the desired
thiosemicarbazone compound. The 1H NMR spectrum of the
mixture of isomers of 2a showed two singlets for H-4 at d 5.92
ppm and 6.19 ppm, respectively, and four broad singlets for the
H2N protons at d 6.36 and 7.24 ppm for the (E)- and at d 6.31 and
7.22 ppm for the (Z)-isomer. The signals for H–N appeared as
singlets at d 8.71 ppm and 8.90 ppm for the (E)- and (Z)-isomers,
respectively. The 13C NMR spectrum also revealed two sets of
signals, which conrmed that the obtained compound exists in
the form of two isomers. The characteristic signals were: d 121.4
ppm and 111.2 ppm (C-4), 150.5 ppm and 149.5 ppm (C-3),
153.2 ppm and 158.4 ppm (C-5) and 178.4 ppm and 178.3
ppm (C]S) for the (E)- and (Z)-isomers, respectively.
The absolute conguration was determined by analysis of
the NOESY cross-peaks involving the amide proton from the
hydrazone moiety. In the major isomer, the proton at d 8.71
ppm showed NOESY correlations with Ha-2 at 2.66 and Hb-2 at
2.07 ppm, which indicated the E conguration, whereas in the
minor isomer the N–H proton at d 8.90 ppm showed a NOESY
cross-peak with H-4 at 6.20 ppm, which corresponds to the Z
conguration (Fig. 3).
3,17-Bis(thiosemicarbazone) 3a also occurs as a mixture of
two isomers. The molecular formula of 3a was deduced to be
C20H30N6S2 from ESI-TOF-MS, which showed that the molecular
weight of this compound was 73 Da higher than the molecular
weight of compound 2a, which indicated that compound 3a had
one more thiosemicarbazone moiety. Also, in the IR spectrum
of 3a the absorption bands for carbonyls at C-3 and C-17 were
missing. Instead, all the characteristic absorption bands for
thiosemicarbazones at 3421, 3240, 1583, 1496, and 1282 cm1
appeared.
From the NMR spectral data it can be seen that the isomers
3a-E and 3a-Z diﬀer in the conguration at the C(3)]N double
bond, whereas at C-17 only one isomer was obtained.Fig. 3 Absolute conﬁguration on the C(3)]N double bond in 2a-E and
2a-Z with the key NOESY correlations.
This journal is © The Royal Society of Chemistry 2016The 13C NMR spectrum of 3a conrmed the presence of 20
carbon signals and also revealed two sets of signals. The major
diﬀerences in the spectral data of 3a compared with those of 2a
were the loss of the carbonyl peak at d 222.4 ppm, which was
previously assigned to C-17 and was replaced by a peak at
d 167.0 ppm (C(17)]N), and the presence of a new peak at
d 178.7 ppm for another C]S group. The other characteristic
signals were: d 121.3 ppm and 111.4 ppm (C-4), 150.7 ppm and
149.7 ppm (C-3), 153.1 ppm and 158.4 ppm (C-5) and 178.3 ppm
and 178.2 ppm (C]S) for 3a-E and 3a-Z, respectively.
The 1H NMR spectrum of 3a also contained two sets of
signals: two singlets for H-4 at d 5.91 for the (E)- and 6.22 ppm
for the (Z)-isomer, and two broad singlet pairs for the H2N
protons from the hydrazone moiety at C-3 at d 6.50 and 7.26
ppm for the (E)- and d 6.45 and 7.23 ppm for the (Z)-isomer. The
broad singlet pair for H2N from the thiosemicarbazone moiety
at C-17 appeared at d 6.53 and 7.18 ppm for both isomers. The
signals for the two H–N protons appeared as singlets at d 8.83
and 8.49 ppm for the (E)-isomer and at d 9.05 and 8.49 ppm for
the (Z)-isomer. The NOESY cross-peaks between NH/Ha-2 and
NH/Hb-2 conrmed the E conguration on the C(3)]N double
bond in the major isomer of 3a. In both isomers, the hydrazone
moiety at C-17 adopted the E conguration, which was
conrmed by the NOESY correlations of NH (8.49 ppm) with Ha-
16 (2.28 ppm) and Hb-16 (2.47 ppm) and the absence of any
correlation with CH3-18. Moreover, inspection of Dreiding
models suggests that steric repulsion between CH3-18 from the
sterane skeleton and the thiosemicarbazone moiety at C-17
prevents the formation of the (Z)-isomer (Fig. 4).
Almost the same patterns in the 1H NMR and 13C NMR
spectra were observed for all the newly synthesized thio-
semicarbazones 2a–e and 3a–e.
When thiosemicarbazones 2a and 3a as mixtures of both
isomers (E and Z) were treated with acetylating agents in basic
media, from each mixture a single new heterocyclic compound
was isolated. Thus, thiadiazoline 4a was formed from the
mixture of 2a and 3,17-bis(thiadiazoline) 5a from the mixture of
3a.
The molecular formula of 4a was deduced to be C23H31N3O3S
from ESI-TOF-MS, which showed a peak at m/z 430.21581
(calculated for C23H32N3O3S [M + H]
+, 430.21589), and that of 5a
to be C28H38N6O4S2 with a peak at m/z 587.24700 (calculated for
C28H39N6O4S2 [M + H]
+, 587.24687).
In the IR spectra new characteristic absorption bands
appeared at 1618 (C]N) and 756 (C–S) cm1 for compound 4aFig. 4 Absolute conﬁguration on the C(17)]N double bond in 3awith
the key NOESY correlations.
RSC Adv., 2016, 6, 34312–34333 | 34315
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View Article Onlineand at 1642, 1615 (C]N) and 722 (C–S) cm1 for compound 5a,
due to ring closure.
In the 1H NMR spectra the absence of signals for the amino
groups from the parent compounds 2a and 3a was evident.
Furthermore, the N-acetyl protons of the thiadiazoline rings in
both compounds were shown as singlets at d 2.11 and 2.19 ppm
for 4a and at d 2.09, 2.12, 2.18 and 2.22 ppm for 5a. The signal
for the alkenyl H-4 proton appeared at about d 5.60 ppm for
both compounds, upeld from the resonance of the corre-
sponding proton in the starting compounds 2a and 3a, which
also indicated the absence of a conjugated imine moiety, which
was present in thiosemicarbazones 2a and 3a. In addition, the
axial proton at C-16 in compound 5a (in the a-position to the
thiadiazoline ring at C-17) resonates separated downeld from
the other ring protons at d 4.35 ppm, owing to the position of
the thiadiazoline ring and the strong anisotropic eﬀect of C]O
in the acetyl moiety bound to N-300.
In the 13C NMR spectra compound 4a showed characteristic
signals at d 141.1 ppm for C-50 and compound 5a at d 146.4 and
149.4 ppm for C-50 and C-500, respectively, owing to (N]C–S),
which indicated the cyclization of the thiocarbamoyl carbon.
Also, the signals for C-3 in compound 4a at d 79.9 ppm and both
C-3 and C-17 in compound 5a at d 81.3 and 94.0 ppm, respec-
tively, were situated upeld from the resonances of the same
carbon atoms in thiosemicarbazones 2a and 3a, which sug-
gested the formation of spiro-thiadiazolines.
The combined use of HSQC, HMBC, COSY and NOESY
(ROESY) spectra enabled the complete 1H and 13C assignment
of thiadiazolines 4a and 5a (see Experimental section).
However, that did not help us to determine the absolute
conguration at C-3. Luckily, in the case of compound 4a we
were able to obtain crystals that were suitable for X-ray analysis,
which conrmed the structure and showed that the absolute
conguration at C-3 was R (Fig. 5).
In the case of 3,17-bis(thiadiazoline) 5a our attempts at
growing crystals that were suitable for X-ray analysis failed.Fig. 5 Molecular structure of 4a with atom numeration. Anisotropic
displacement ellipsoids are drawn at the 30% probability level.
Hydrogen atoms are depicted as spheres of arbitrary radius. Bond
lengths (A˚): S10–C50 ¼ 1.739 (3), S10–C3 ¼ 1.852 (3), N40–N30 ¼ 1.397
(3), N30–C3¼ 1.487 (4), N40–C50 ¼ 1.282 (4), C4–C5¼ 1.321 (5), N–C50
¼ 1.377 (4), N–C20 ¼ 1.342 (4), N30–C22 ¼ 1.345 (4), O1–C17 ¼ 1.192
(7), O2–C20 ¼ 1.210 (5), O3–C22 ¼ 1.234 (4). Valence angles (): C50–
S10–C3¼ 89.86 (13), N30–C3–S10 ¼ 102.01 (17), C4–C3–C2¼ 111.2 (3).
Torsion angles (): C50–N40–N30–C22¼176.3 (4), N30–N40–C50–N¼
178.5 (3), C3–C4–C5–C10 ¼ 1.5 (5).
34316 | RSC Adv., 2016, 6, 34312–34333Considering the fact that the conguration at C-3 is already
known (by comparison of the spectral data with those of
compound 4a and from its X-ray analysis), the conguration at
C-17 was determined by detailed analysis of the NMR spectra as
well as by the examination of Dreiding molecular models. In the
absence of any COSY or NOESY interactions that include the N-
acetyl protons of the thiadiazoline ring at C-17, the most helpful
were the protons bonded to C-16 (d 31.0 ppm) at d 2.06 ppm and
especially the other proton, which resonates separated down-
eld from the other ring protons at d 4.35 ppm. This signal
showed a NOESY correlation with both Ha-15 at d 1.76 and Hb-
15 at d 1.42 ppm, as well as with the 18-Me group at d 0.95 ppm,
and, according to the Dreiding models, was attributed to Hb-16.
Because the apparent disparity in the 1H NMR shis in the case
of Hb indicates strong deshielding owing to the anisotropic
eﬀect of the C]O group from the acetyl moiety bound to N-30,
the conguration at C-17 in 5a must be R (Fig. 6).
The mechanism of heterocyclization that leads to the
formation of steroidal 1,3,4-thiadiazolines has already been
described.21,50,51 It is proposed that the thiadiazoline ring is
closed by the attack of the sulfur atom (which is a better
nucleophile) of the thiosemicarbazone moiety on the steroidal
sp2 carbon, preferentially from the axial side, which enables the
bulky NAc group to occupy the equatorial orientation, giving
minimum steric hindrance andmaximum stability.51 Therefore,
the formation of the 3R and 3R,17R compounds is preferred
over that of their isomers.
In the same way, the structures of thiadiazolines 4a–e and
3,17-bis(thiadiazolines) 5a–d were conrmed by their charac-
terization data.
The exception was 3,20-bis(thiadiazoline) 5e derived from
3,20-bis(thiosemicarbazone) 3e, which was obtained as
a mixture of two diastereoisomers (20R and 20S, in the ratio of
approximately 1.2 : 1, as deduced by comparing the peak areas
of H–C(4) and the H3C-18 and H3C-19 methyl groups in the
corresponding 1H NMR spectrum) with diﬀerent congurations
at C-20. As we could not separate the isomers, in the absence of
any NOESY correlations it was not possible to conrm the
complete stereostructure. These diﬃculties were accompanied
by possible rotation around the C(17)–C(20) axis, which was
conrmed by inspection of the Dreiding models. In this case,
there was no steric repulsion between the bulky NAc group and
the sterane skeleton, so closure of the thiadiazoline ring could
occur by the attack of the sulfur atom of the thiosemicarbazone
moiety on the C-20 sp2 carbon atom from either side, which
enabled the formation of both isomers.Fig. 6 3D representation of the proposed structure of 5a and
conﬁguration at C-17 on the basis of NOESY correlation.
This journal is © The Royal Society of Chemistry 2016
Fig. 7 Fourfold-symmetrical hydrogen-bonded molecular ring,
a feature of the crystal packing in 4a. Hydrogen bond data: N–H¼ 0.78
(4) A˚, H/O3i ¼ 2.05 (4) A˚, N/O3i ¼ 2.801 (4) A˚,:(N–H/O3i) ¼ 159
(4). Symmetry code (i): y + 2, x, z.
Paper RSC Advances
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View Article OnlineMolecular and crystal structure of 1,3,4-thiadiazoline 4a
The molecular structure of compound 4a is depicted in Fig. 5,
together with relevant structural data. The compound crystal-
lizes in the non-centrosymmetric space group I4, and its abso-
lute conguration was assigned unambiguously by reference to
the known chirality of the steroid atoms. The steroidal core has
a common structure, with rings B and C in chair conformations
and the ve-membered ring D in an envelope conformation on
C-14. The cyclohexene ring A adopts a half-chair conformation
(torsion angle C3–C4–C5–C10 ¼ 1.5 (5)) induced by the C4–
C5 double bond (1.321 (5) A˚). To this steroidal core, a thiadia-
zoline ring is attached at the C-3 position, thus forming a spiro
system. The X-ray structural study revealed that this newly
formed stereocenter has R conguration, with S10 in the axial
and N30 in the equatorial position relative to ring A.
There are a few structurally characterized compounds that
contain a six-membered carbon ring and a thiadiazoline ring
fused in a spiro system,34,50,52 but none of these is a steroid
derivative. Generally, the thiadiazoline ring in 4a has virtually
the same structural parameters as are found in literature data
concerning compounds with 1,3,4-thiadiazoline rings.34,50,52,53 It
slightly deviates from planarity, adopting an envelope confor-
mation with C-3 as a pivot atom. The sulfur atom S-10 is asym-
metrically bonded to two carbon atoms in a way that the bond
with sp2-hybridized C-50 is shorter (1.739 (3) A˚) than the bond
with sp3-hybridized C-3 (1.852 (3) A˚). The N40–C50 distance
(1.282 (4) A˚) corresponds to a localized double bond. The only
diﬀerence is the fact that in 4a the acetyl group at N-30 and the
acetylamino group at C-50 are coplanar with the thiadiazoline
fragment (s(C50–N40–N30–C22) ¼ 176.3 (4); s(N30–N40–C50–N)
¼ 178.5 (4)), in contrast to other structures in which acetyl
groups signicantly deviate from coplanarity with the ring (121
< |s(C50–N40–N30–C22)| < 170). The reason for this is the
absence of any steric hindrance in 4a, in contrast to that found
in other structures.
From the crystallographic point of view, the crystal packing
of the molecules reveals an interesting feature, namely, the
acetylamino NH group acts as a hydrogen bond donor to the
acetyl oxygen from a neighboring molecule in a geometrical
arrangement where four molecules form a molecular ring with
crystallographic fourfold symmetry (Fig. 7). In this way,
a supramolecular tetramer is formed, which is described by the
R4
4(28) graph set.54 The central void created by this arrangement
is lled with disordered DMSO molecules.Biological evaluation
Cytotoxic activity. Cytotoxic activity in vitro was tested
against six human malignant cell lines: cervical adenocarci-
noma HeLa, two breast cancer cell lines (originally estrogen
receptor-negative and progesterone receptor-negative MDA-MB-
453 cells and estrogen receptor-positive and progesterone
receptor-positive MDA-MB-361 cells), chronic myelogenous
leukemia K562 cells, colon adenocarcinoma LS174 cells and
lung adenocarcinoma A549 cells. Also, cytotoxic activity was
tested against normal human lung broblasts MRC-5 (Table 1).
Compounds 2a, 2b, 2c, 2e, 5a and 5d, which exerted the mostThis journal is © The Royal Society of Chemistry 2016pronounced cytotoxic activity, were further screened for cyto-
toxic activity against normal human peripheral blood mono-
nuclear cells (PBMC), which were non-stimulated and
stimulated to proliferate with the mitogen phytohaemag-
glutinin (PHA).
Against K562 cells, compounds 2a, 2b, 2c, 2e, 3a and 5a
showed strong cytotoxic activity, with IC50 values of 11.3, 6.7,
6.7, 10.7, 11.2 and 8.8 mM, respectively. Compounds 3b, 3c and
5d showed moderate activity, with IC50 values of 28.1, 30.3 and
36.4 mM, whereas compounds 2d and 4a exhibited weak activity
against this cell line at 51.1 and 75.7 mM, respectively. Towards
cervical adenocarcinoma HeLa cells, compounds 2b, 2e and 5a
exerted strong cytotoxic activity, with IC50 values of 7.6, 8.9 and
7.8 mM, respectively, whereas compounds 2a, 2c, 3c and 5b were
slightly less active, with IC50 values of 18.1, 17.3, 14.3 and 21.2
mM, respectively. Compounds 3a, 3b, 5c and 5d showed
moderate activity, with IC50 values from 27.7 to 43.9 mM,
whereas compounds 4a–e were almost inactive against this cell
line.
Compounds 2b, 2c, 2e and 5a exhibited strong activity
against MDA-MB-453 cells, with IC50 values of 6.8, 6.9, 6.9 and
11.0 mM, respectively, whereas compounds 2a, 5b, 5c and 5d
showedmoderate activity, with IC50 values from 18.0 to 44.4 mM.
All the other compounds were practically inactive against this
cell line. Towards the MDA-MB-361 cell line, compound 2e
exerted strong cytotoxic activity, with an IC50 value of 8.7 mM,
whereas compounds 2b and 2c were less active, with IC50 values
of 20.7 and 18.7 mM, respectively. Compound 5d showed
moderate activity, with an IC50 value of 54.1 mM, whereas the
other compounds tested were practically inactive. Towards
colorectal adenocarcinoma LS174 cells, compounds 2e and 5a
showed a strong dose-dependent cytotoxic eﬀect, with IC50
values of 9.2 and 12.6 mM, respectively, compounds 2b, 2c, and
5dmoderate and compound 2aweak activity, with IC50 values of
35.2, 26.2, 42.6 and 61.3 mM, respectively.
Against human lung adenocarcinoma A549 cells,
compounds 2a, 2b, 2c, 2e and 5a exhibited activity that wasRSC Adv., 2016, 6, 34312–34333 | 34317
Table 1 In vitro cytotoxic activity of investigated compounds
Comp.
IC50  S.D. (mM)
HeLa MDA-MB-453 MDA-MB-361 K562 LS174 A549 MRC-5
2a 18.1  3.3 44.4  2.9 144.1  36.6 11.3  2.2 61.3  13.0 10.3  0.7 7.7  1.1
2b 7.6  0.2 6.8  0.2 20.7  6.0 6.7  0.2 35.2  11.6 8.9  0.5 6.5  0.1
2c 17.3  6.8 6.9  0.3 18.7  8.9 6.7  0.3 26.2  6.0 9.5  0.5 7.2  1.3
2d z200 154.3  28.1 183.4  5.2 51.1  15.4 176.7  40.3 178.8  25.5 173.6  45.8
2d-OAc 43.9  4.9 43.7  5.9 z200 10.7  1.5 z200 51.2  7.7 48.1  2.7
2e 8.9  1.6 6.9  0.3 8.7  3.1 6.6  0.2 9.2  3.9 8.6  0.8 6.7  0.5
3a 42.5  1.9 193.0  12.1 >200 11.2  0.4 >200 >200 >200
3b 31.5  3.3 110.8  16.5 z200 28.1  1.5 >200 z200 >200
3c 14.3  7.3 78.5  21.6 >200 30.3  7.5 >200 z200 >200
3d 131.4  6.2 183.7  17.1 197.4  3.6 90.5  13.4 194.8  4.5 >200 >200
3e 182.3  25.0 191.5  25.0 195.5  6.3 158.9  23.5 191.7  11.6 187.4  12.6 186.4  23.6
4a 199.2  1.3 >200 >200 75.7  17.2 163.8  49.3 >200 >200
4b >200 >200 >200 192.8  12.4 >200 >200 >200
4c 185.2  20.9 178.2  34.9 >200 181.2  32.6 >200 >200 >200
4d-OH >200 >200 >200 195.6  7.7 >200 >200 >200
4d-OAc 121.6  10.7 141.4  24.4 170.4  41.9 80.5  9.9 >200 195.6  7.7 >200
4e 108.2  18.3 167.9  34.9 >200 195.8  7.2 >200 187.4  1.0 >200
5a 7.8  0.3 11.0  1.9 >200 8.8  1.3 12.6  3.8 20.6  1.3 12.7  2.0
5b 21.2  1.5 18.0  1.7 >200 163.6  51.4 >200 175.3  32.5 145.8  31.5
5c 27.7  11.6 29.0  9.3 >200 157.2  60.5 182.5  30.3 121.0  34.3 26.2  8.7
5d 37.2  3.0 30.4  7.1 54.1  13.1 36.4  2.0 42.6  3.0 35.6  5.0 38.6  8.8
5e 151.8  28.7 102.8  2.9 >200 136.5  46.9 200  0.0 132.4  37.2 159.3  40.5
TSCa 176.8  9.2 37.7  39.7 23.2  2.6 18.0  0.6 44.5  11.4 176.3  6.2 93.9  16.6
1a 194.2  8.2 133.2  39.7 >200 190.5  16.5 180.5  27.6 >200 >200
1b 76.7  7.5 109.2  39.7 188.7  16.0 177.1  6.5 z200 165.1  1.1 191.0  9.6
1c 95.5  18.8 128.3  8.1 z200 z200 z200 191.8  14.1 >200
1d z200 199.1  1.6 >200 197.8  3.8 >200 >200 >200
1e 21.2  1.6 43.7  9.3 124.6  39.4 64.3  7.8 158.8  58.3 186.4  11.8 157.2  15.2
Cisplatin 2.1  0.2 3.6  0.5 17.1  1.2 5.4  0.3 17.8  0.6 14.4  0.7 9.2  0.2
a Thiosemicarbazide.
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View Article Onlinecomparable to, or slightly better than, cisplatin, with IC50 values
of 10.3, 8.9, 9.5, 8.6 and 20.6 mM, respectively. Their cytotoxic
activity was higher against normal human fetal lung broblasts
MRC-5, with IC50 values of 7.7, 6.5, 7.2, 6.7 and 12.7 mM.
However, cisplatin, a chemotherapy drug that is used to treat
diﬀerent types of cancer, including non-small-cell lung cancer,
showed a similar lack of selectivity.
The results mentioned above indicate that of the examined
malignant cell lines, K562 cells were the most sensitive to the
cytotoxic action of the newly synthesized steroid derivatives,
especially 2a–c, 2e, 3a, 5a and 5d. HeLa cells demonstrated high
sensitivity to 2a–c, 2e, 3c, 5a, 5b and 5d, and MDA-MB-453 cells
to 2b, 2c, 2e, 5a, 5b and 5d. A549 cells were very sensitive to the
cytotoxic activity of 2a, 2b, 2c, 2e and 5a, whereas LS174 cells
were sensitive to the activity of 2c, 2e and 5a. MDA-MB-361 cells
showed the lowest sensitivity to all the investigated compounds
except 2b, 2c and 2e (Table 1).
By examining the IC50 values in Table 1, it can be concluded
that thiosemicarbazones 2a, 2b, 2c and 2e (as well as cisplatin,
which served as a positive control) exhibited the highest cyto-
toxic activities against all cell lines, which were much higher
than those of the corresponding starting steroids 1a–e or thio-
semicarbazide itself. Bis(thiosemicarbazones) 3a–e exhibited
much lower activities, which suggested that the introduction of34318 | RSC Adv., 2016, 6, 34312–34333another thiosemicarbazone group was not appropriate for
cytotoxic activity against almost all the examined cancer cell
lines. This pointed to the fact that, in addition to the thio-
semicarbazone moiety at C-3, for the activity of these
compounds a substituent at C-17 was also responsible. In
compounds 2a, 2b and 2c, this was the 17-oxo group and in
compound 2e the 17-acetyl group, which both signicantly
increased the activities of these compounds. However, it is well
known that the activity of a new compound does not only
depend on its functional groups but also on its three-
dimensional orientation. Because we are dealing with insepa-
rable mixtures of isomers (Z and E), it is impossible from this
perspective to say which one actually had a greater cytotoxic
eﬀect upon the cell lines used in this study, especially because
there are not many literature data regarding this matter. The
only available literature that can be applied to steroidal thio-
semicarbazone isomers describes the diﬀerence in the cytotoxic
activity of E- and Z-steroidal oximes8,49 and, according to these
references, there were no signicant diﬀerences in anti-
proliferative activity between the isomers.
A comparison of the derivatives with spiro-1,3,4-
thiadiazoline rings indicates that the compounds with two
spiro-1,3,4-thiadiazoline rings (5a–d) displayed more
pronounced cytotoxicity than those with one (4a–e and 5e),This journal is © The Royal Society of Chemistry 2016
Table 3 Coeﬃcient of selectivity (Cs) in the anticancer activity of 2a,
2b, 2c, 2e, 5a and 5d as a ratio of the IC50 values for PBMC and
malignant cells
Comp.
Cs
PBMC/
HeLa
PBMC/
MDA-MB-453
PBMC/
K562
PBMC/
LS174
PBMC/
A549
2a 2.4 1.0 3.9 0.7 4.3
2b 2.1 2.3 2.4 0.5 1.8
2c 1.4 3.6 3.7 1.0 2.6
2e 2.3 2.9 3.0 2.2 2.3
5a >25.5 >18.1 >22.8 >15.9 >9.7
5d >5.4 >6.6 >5.5 >4.7 >5.6
CDDPa 28.9 16.9 11.3 3.4 4.2
a Cisplatin.
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View Article Onlinewhich were practically inactive against all the tested malignant
cell lines. Taking this into account, it can be concluded that the
spiro heterocyclic substituent at the C-17 position, as well as the
presence of the a,b-unsaturated thiosemicarbazone moiety at C-
3, enhanced the activity of the tested compounds.
If the type of steroidal moiety is considered, it is evident that
3-thiosemicarbazones 2a, 2b, 2c and 2e showed similar activi-
ties towards the majority of cell lines tested. The absence of the
19-methyl group, the substituent at C-17 (17-oxo or 17-COCH3)
or the degree of unsaturation of the parent steroids were
observed not to alter the extent of cytotoxic activity signicantly.
The exception was 11a-hydroxy-3-thiosemicarbazone 2d, which
was practically inactive against all the tested malignant cell
lines, which indicated that the substitution of a hydrogen atom
by a proton-donating OH group in the 11a position led to
a dramatic decrease in activity. This nding was supported by
the results obtained for other 11a-hydroxy derivatives,
compounds 3d and 4d-OH, which were also inactive. In
contrast, the introduction of an OCOCH3 group in the 11a
position (compounds 2d-OAc and 4d-OAc) much improved the
activity of these compounds. Regarding 3,17-bis(thiadiazo-
lines), from the data presented in Table 1 it can be seen that
compounds 5b, with an androstene moiety, and 5c, with D9–11
unsaturation, showed good cytotoxic activity, but only against
HeLa and MDA-MB-453 cell lines. Compound 5d, with an 11a-
OCOCH3 group, showed moderate activity against all the
examined cell lines, whereas compound 5a, with a 19-noran-
drostene moiety, exhibited very good activity against all the cell
lines except MDA-MB-361.
The anticancer potential of compounds 2a, 2b, 2c, 2e, 5a and
5d, which exhibited the most pronounced cytotoxic activity
against all the examined cancer cell lines, was further examined
against normal human non-stimulated andmitogen-stimulated
PBMC. The tested compounds showed higher cytotoxic activi-
ties against K562, HeLa, MDA-MB-453, LS174 and A549 cells in
comparison with normal non-stimulated and PHA-stimulated
PBMC. The activity of compounds 2e, 5a and 5d was in most
cases less pronounced against non-stimulated than against
stimulated PBMC (Table 2).
The selectivity in the anticancer activity of compounds 5a
and 5d was very high, especially against HeLa and K562 cell
lines (Tables 3 and 4). In addition, compound 2a showedTable 2 In vitro cytotoxic activity of 2a, 2b, 2c, 2e, 5a and 5d against
PBMC
Comp.
IC50  S.D. (mM)
PBMCb PBMC + PHAb
2a 44.1  13.7 40.1  13.8
2b 15.7  3.0 14.3  4.5
2c 24.9  14.8 26.9  22.7
2e 20.0  14.3 13.1  6.1
5a >200 197.3  3.8
5d >200 159.5  56.3
CDDPa 60.8  12.6 23.6  4.7
a Cisplatin. b From four independent experiments.
This journal is © The Royal Society of Chemistry 2016notably higher cytotoxic activity against K562 and A549 cells
than towards normal PBMC.
In order to elucidate the mechanisms of the cytotoxic activity
of the steroidal compounds, an examination of changes in the
cell cycle of myelogenous leukemia K562 cells and human
cervical adenocarcinoma HeLa cells treated with compounds
2a, 2b, 2c, 2e, 5a and 5d for 24 and 48 h was performed. Analysis
of the changes in the cell cycle phase distribution of HeLa cells
caused by these steroidal compounds applied at concentrations
of IC50 and 2IC50 revealed a signicant time- and dose-
dependent increase in cells in the subG1 phase compared
with control cells (Fig. 8). At both tested concentrations,
compounds 2a, 2b, 2c and 2e exerted to some extent a stronger
apoptotic eﬀect with respect to compounds 5a and 5d.
Compound 5d applied at a concentration of 2IC50 led to
a signicant accumulation of HeLa cells in the S phase aer
treatment for 24 and 48 h. The same eﬀect of compound 5d on
HeLa cells was observed aer treatment for 48 h at a concen-
tration of IC50. Treatment of K562 cells with concentrations of
IC50 of the investigated steroid derivatives induced signicant
time-dependent increases in cells in the subG1 phase with
respect to the control cell sample (with the exception of
compounds 2a and 5a aer exposure for 24 h). In addition, all
the investigated compounds at a concentration of 2IC50 trig-
gered a signicant increase in the percentage of K562 cells in
the subG1 phase aer exposure for 24 h and 48 h (Fig. 9).
To investigate the possible pro-apoptotic activity of the
steroidal compounds 2a, 2b, 2c, 2e, 5a and 5d against cervical
adenocarcinoma HeLa cells, morphological analysis was per-
formed by uorescence microscopy of target cells stained with
acridine orange-ethidium bromide and exposed for 24 h to
these agents.
As can be seen in Fig. 10, the investigated steroid derivatives
at concentrations of 2IC50 induced typical morphological hall-
marks of apoptosis in exposed HeLa cells – chromatin
condensation, shrinkage of the nucleus and fragmentation of
the nucleus, as well as orange-red stained cells in the late stages
of apoptosis.
Identication of HeLa cells in diﬀerent stages of apoptosis
induced by the examined steroid derivatives was performed byRSC Adv., 2016, 6, 34312–34333 | 34319
Table 4 Coeﬃcient of selectivity (Cs) in the anticancer activity of 2a, 2b, 2c, 2e, 5a and 5d as a ratio of the IC50 values for PBMC + PHA and
malignant cells
Comp.
Cs
PBMC + PHA/HeLa PBMC + PHA/MDA-MB-453 PBMC + PHA/K562 PBMC + PHA/LS174 PBMC + PHA/A549
2a 2.2 0.9 3.6 0.7 3.9
2b 1.9 2.1 2.2 0.4 1.6
2c 1.6 3.9 4.0 1.0 2.8
2e 1.5 1.9 2.0 1.4 1.5
5a 25.2 17.9 22.5 15.7 9.6
5d 4.3 5.3 4.4 3.7 4.5
CDDPa 11.4 6.5 4.4 1.3 1.4
a Cisplatin.
Fig. 8 Changes in the cell cycle phase distribution of HeLa cells. Cell cycle analysis of HeLa cells treated with compounds 2a, 2b, 2c, 2e, 5a and
5d at concentrations corresponding to IC50 (A, C) and 2IC50 (B, D) after 24 h (A, B) and 48 h (C, D). The results are presented as the mean S.D. of
three independent experiments. ANOVA was performed for statistical analysis. *(p < 0.05).
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View Article Onlineow cytometry aer staining with annexin V-FITC/PI. In Fig. 11,
for each cell sample the percentages of annexin V+/PI early
apoptotic cells, annexin V+/PI+ late apoptotic/secondary necrotic
cells and annexin V/PI+ dead cells are shown. Increased
percentages of early apoptotic and end-stage apoptotic/
secondary necrotic HeLa cells were measured in the samples
treated for 24 h with concentrations of 2IC50 of compounds 2a,
2b, 2c, 2e, 5a and 5d in comparison with the control cell sample.
In addition, there was an increase in the percentage of dead
HeLa cells (annexin V/PI+) for each of the tested steroidal
compounds.
For further mechanistic studies of the mode of cell death
induced by the most active compounds 2a, 2b, 2c, 2e, 5a and 5d
in cervical adenocarcinoma HeLa cells, the possible activation
of caspase-3, caspase-8 and caspase-9 was investigated by using
specic caspase inhibitors. The observed decrease in the34320 | RSC Adv., 2016, 6, 34312–34333percentages of subG1 HeLa cells pretreated with each of the
caspase inhibitors and exposed to the tested compounds, in
comparison with the percentages of subG1 cells in samples
exposed only to the compounds, points to the pro-apoptotic
activity of the compounds. All the tested steroidal compounds
activate extrinsic and intrinsic apoptotic signaling pathways in
HeLa cells (Fig. 12).
To investigate the anti-angiogenic potential of the most
active and selective steroid derivatives 2a, 2b, 2c, 2e, 5a and 5d,
an endothelial cell tube formation assay was performed. When
human endothelial EA.hy926 cells are plated on the surface of
a Matrigel matrix, they begin to extend, connect and rearrange
in order to form capillary-like tube structures and polygonal
structures.55 Representative photomicrographs of control
EA.hy926 cells and cells exposed to sub-toxic concentrations of
IC20 of the tested compounds aer 20 h are shown in Fig. 13. AsThis journal is © The Royal Society of Chemistry 2016
Fig. 9 Changes in the cell cycle phase distribution of K562 cells. Cell cycle analysis of K562 cells treated with compounds 2a, 2b, 2c, 2e, 5a and
5d at concentrations corresponding to IC50 (A, C) and 2IC50 (B, D) after 24 h (A, B) and 48 h (C, D). The results are expressed as the mean S.D. of
three independent experiments. ANOVA was performed for statistical analysis. *(p < 0.05).
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View Article Onlinecan be seen, each of the investigated steroidal compounds
showed the ability to decrease angiogenesis in vitro. Compound
5a exerted the strongest anti-angiogenic activity. Compound 2a
also exhibited a remarkable anti-angiogenic eﬀect, whereas
compounds 2b, 2c, 2e and 5d were less eﬀective in inhibiting
angiogenesis, especially 5d, which exerted the weakest anti-
angiogenic action.
The brine shrimp test. In the brine shrimp test, general
toxicity against nauplii of the brine shrimp Artemia salina was
evaluated. This assay has been established as a safe, practical,
and economic method for the determination of the bioactivity
of synthetic compounds,56 and is considered to show a good
correlation with cytotoxicity tests.57 Compounds 5a–d, which
displayed high cytotoxicity against HeLa and MDA-MB-453,
were also found to be the most active in the brine shrimp
assay, whereas compounds 2a–e and 3a–e, as well as thiadia-
zolines 4a–e, were found to be less active (Table 5).
These results indicate that the bis(thiadiazoline) structure
enhances the activity of the newly synthesized compounds, but
also that other structural requirements must obviously be
satised.
Antimicrobial activity. The in vitro antimicrobial activity of
all given compounds 2–5 was tested against Gram-positive
bacteria: Staphylococcus aureus, Kocuria rhizophila, Clostridium
sporogenes and Bacillus subtilis, Gram-negative bacteria:
Escherichia coli, Proteus hauseri, Pseudomonas aeruginosa and
Salmonella enterica, as well as against fungal species: Candida
albicans, Saccharomyces cerevisiae and Aspergillus brasiliensis by
an agar well diﬀusion method.
Almost all the compounds, except 3a–e, exhibited weak
inhibitory activity against the Gram-positive bacteria C.This journal is © The Royal Society of Chemistry 2016sporogenes and K. rhizophila and against the Gram-negative
bacterium P. aeruginosa. In all cases, the inhibition zones
were much smaller than those for amikacin (Table 6). All the
novel synthesized compounds, except 3e, were found to have
very weak antifungal activity against A. brasiliensis.
Moreover, compounds 2b, 2e, 3c, 4b–e, 5b, 5d and 5e
exhibited weak inhibitory activity against the other two fungi
tested, C. albicans and S. cerevisiae (Table 7).
Experimental
Chemistry
Removal of solvents was carried out under reduced pressure.
Thin-layer chromatography (TLC) was performed using
aluminium plates coated with silica gel 60 F254 (Merck) and
ash column chromatography (FCC) was performed on silica
gel (0.040–0.063 mm, Merck). TLC spots were detected with
50% aq. H2SO4 followed by heating. Melting points were
determined on a WRS-1B digital melting point apparatus and
are uncorrected. Optical rotations were measured in CHCl3,
CH3OH, or CHCl3/CH3OH (3 : 1) using a Rudolph Research
Analytical Autopol IV automatic polarimeter at 20 C. IR spectra
were recorded on a PerkinElmer 1725X FT-IR spectrophotom-
eter. NMR spectra were recorded on a Varian Gemini-200
spectrometer (1H at 200 MHz; 13C at 50 MHz) or a Bruker
Avance 500 MHz spectrometer (1H at 500 MHz; 13C at 125 MHz)
in DMSO, CDCl3 and/or CD3OD at room temperature using
SiMe4 as internal standard, d in ppm, J in Hz. HRMS spectra
were recorded on an Agilent 6210 LC ESI-MS TOF spectrometer.
Androst-4-ene-3,17-dione, 19-norandrost-4-ene-3,17-dione,
androsta-4,9(11)-diene-3,17-dione, 11a-hydroxyandrost-4-ene-RSC Adv., 2016, 6, 34312–34333 | 34321
Fig. 10 Induction of apoptosis in HeLa cells. Photomicrographs of
control HeLa cells andHeLa cells stainedwith acridine orange/ethidium
bromide and exposed for 24 h to cisplatin and the investigated
compounds 2a, 2b, 2c, 2e, 5a and 5d, as described in the Materials and
methods section. The concentrations applied of the tested compounds
corresponded to values of 2IC50 determined for 72 h.
Fig. 11 Flow cytometry analysis of control and treated HeLa cells
stained with annexin V-FITC and propidium iodide. The results are
shown as the mean  S.D. of two independent experiments. A+P
(FITC-annexin V positive, PI negative), A+P+ (FITC-annexin V positive,
PI positive), and AP+ (FITC-annexin V negative, PI positive).
Fig. 12 Identiﬁcation of target caspases. Eﬀects of speciﬁc caspase
inhibitors (Z-DEVD-FMK – caspase-3 inhibitor; Z-IETD-FMK – cas-
pase-8 inhibitor; Z-LEHD-FMK – caspase-9 inhibitor) on the
percentages of subG1 HeLa cells treated with compounds 2a, 2b, 2c,
2e, 5a and 5d at concentrations corresponding to 2IC50 for 24 h.
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View Article Online3,17-dione and progesterone were purchased from Galenika AD
(Beograd) and were recrystallized from a suitable solvent.General procedure for the synthesis of thiosemicarbazones
and bis(thiosemicarbazones)
Thiosemicarbazide (3.16 mmol or 6.3 mmol) was added to
a solution of steroid (1a–e) (3.16 mmol) in dried ethanol (150 or
300 mL). The reaction mixture was reuxed for 5 h with stirring34322 | RSC Adv., 2016, 6, 34312–34333and monitored by TLC. The pH of the mixture was adjusted to
4.5 with CH3COOH (about 5 mL). Aer completion of the
reaction, the solvent was removed under reduced pressure. The
residue was crystallized or chromatographed by FCC using
diﬀerent solvents as eluents (the eluents and ratio are
mentioned in each experiment). In all cases, the products were
obtained as mixtures of two diastereoisomers (E and Z), which
could not be separated. All spectra were recorded using these
mixtures.
Mixture of 2a (E/Z). Starting with 860 mg 19-norandrost-4-
ene-3,17-dione (1a), elution with toluene/EtOAc (8/2) gave 2a
(727 mg, 66.7%). Rf ¼ 0.66 (toluene/EtOAc, 6 : 4, double
development). Mp > 218 C (decomp.). IR (ATR/cm1): 3422 and
3246 (NH), 1732 (C]O), 1586, 1497 (C]N), 1285 (C]S). ESI-
TOF-MS: m/z for C19H27N3OS [M + H]
+: calcd 346.19476,
found 346.19388.
(E)-19-Norandrost-4-ene-3,17-dione 3-thiosemicarbazone
(2a-E). 1H-NMR (500MHz, CDCl3): 0.82 (m, 1H, H-9), 0.93 (s, 3H,
H3C-18), 1.09 (m, 1H, Ha-7), 1.23–1.41 (m, 4H, Ha-11, Hb-11,
Ha-12, H-14), 1.46 (dq, J ¼ 3, 12 Hz, 1H, H-8), 1.56 (m, 1H, Hb-
15), 1.77–2.14 (m, 7H), 2.19–2.31 (m, 2H), 2.47 (dd, J ¼ 19.0, 9.0
Hz, 1H, Hb-16, partially overlapped with Hb-6), 2.50 (m, 1H, Hb-
6), 2.65 (dt, J ¼ 16.0, 4.0 Hz, 1H, Ha-2), 5.92 (s, 1H, H-4), 6.36
and 7.24 (2bs, 2H, NH2), 8.71 (s, 1H, NH).
13C NMR (125 MHz,
CDCl3): 220.6 (s, C-17), 178.4 (s, C]S), 153.2 (s, C-5), 150.5 (s, C-
3), 121.4 (d, C-4), 50.2 (d, C-14), 49.4 (d, C-9), 47.7 (s, C-13), 41.6
(d, C-10), 39.9 (d, C-8), 35.7 (t, C-16), 34.6 (t, C-6), 31.3 (t, C-12),
29.9 (t, C-7), 25.9 (t, C-11), 25.8 (t, C-1), 22.7 (t, C-2), 21.5 (t, C-15),
13.7 (q, C-18).This journal is © The Royal Society of Chemistry 2016
Table 5 Results of the brine shrimp test for investigated compounds
Comp. LC50 (mM mM
1)
2a 0.597
2b 0.439
2c 0.663
2d 0.551
2d-OAc 0.386
2e 0.670
3a 0.599
3b 0.465
3c 0.420
3d 0.481
3e 0.300
4a 0.601
4b 0.579
4c 0.874
4d-OH 0.561
4d-OAc 0.299
4e 0.430
5a 0.213
5b 0.273
5c 0.327
5d 0.224
5e 0.380
Fig. 13 Eﬀects on in vitro angiogenesis of EA.hy926 cells. Photomi-
crographs of control EA.hy926 cells and cells exposed to sub-toxic
concentrations of IC20 of compounds 2a, 2b, 2c, 2e, 5a and 5d after 20 h.
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View Article Online(Z)-19-Norandrost-4-ene-3,17-dione 3-thiosemicarbazone
(2a-Z). 1H-NMR (500MHz, CDCl3): 0.84 (m, 1H, H-9), 0.93 (s, 3H,
H3C-18), 1.12 (m, 1H, Ha-7), 1.23–1.41 (m, 4H), 1.46 (dq, J¼ 3.0,
12.0 Hz, 1H, H-8), 1.56 (m, 1H, Hb-15), 1.77–2.14 (m, 7H), 2.19–
2.31 (m, 2H), 2.40 (dt, J ¼ 15.0, 4.0 Hz, 1H, Ha-2), 2.47 (dd, J ¼
19.0, 9.0 Hz, 1H, Hb-16), 2.50 (m, 1H, Hb-6), 6.19 (s, 1H, H-4),
6.31 and 7.22 (2bs, 2H, NH2), 8.90 (s, 1H, NH).
13C NMR (125
MHz, CDCl3): 220.5 (s, C-17), 178.3 (s, C]S), 158.6 (s, C-5), 149.5
(s, C-3), 111.2 (d, C-4), 50.1 (d, C-14), 50.0 (d, C-9), 47.7 (s, C-13),
43.2 (d, C-10), 40.0 (d, C-8), 35.8 (t, C-6), 35.7 (t, C-16), 31.3 (t, C-
12), 30.4 (t, C-7), 25.9 (t, C-11), 25.5 (t, C-1), 22.7 (t, C-2), 21.5 (t,
C-15), 13.7 (q, C-18).
Further elution with toluene/EtOAc (6/4) gave 3a (79.4 mg,
12%).
Mixture of 3a (E/Z). Starting with 860 mg 19-norandrost-4-
ene-3,17-dione (1a), elution with toluene/EtOAc (8/2) gave 2a
(115.5 mg, 10.6%). Further elution with toluene/EtOAc (6/4)
gave 3a (723 mg, 55.0%). Rf ¼ 0.46 (toluene/EtOAc, 6 : 4,
double development). Mp > 127 C (decomp.). IR (ATR/cm1):This journal is © The Royal Society of Chemistry 20163421 and 3240 (NH), 1583, 1496 (C]N), 1282 (C]S). ESI-TOF-
MS: m/z for C20H30N6S2 [M + H]
+: calcd 419.20461, found
419.20335.
(E)-19-Norandrost-4-ene-3,17-dione bis(thiosemicarbazone)
(3a-E). 1H-NMR (500MHz, CDCl3): 0.81 (m, 1H, H-9), 0.94 (s, 3H,
H3C-18), 1.08 (m, 1H, Ha-7), 1.20 (m, 1H, H-14), 1.24–1.46 (m,
4H), 1.51 (m, 1H, Hb-15), 1.81–2.12 (m, 7H), 2.17–2.34 (m, 2H),
2.41–2.54 (m, 2H), 2.67 (dt, J ¼ 16.0, 4.0 Hz, 1H, Ha-2), 5.91 (s,
1H, H-4), 6.50 and 7.26 (2bs, 2H, NH2), 6.53 and 7.18 (2bs, 2H,
NH2), 8.49 (s, 1H, NH), 8.83 (s, 1H, NH).
13C NMR (125 MHz,
CDCl3): 178.7 (s, C]S), 178.3 (s, C]S), 167.0 (s, C-17), 153.1 (s,
C-5), 150.7 (s, C-3), 121.3 (d, C-4), 52.1 (d, C-14), 49.5 (d, C-9),
44.8 (s, C-13), 41.6 (d, C-10), 39.7 (d, C-8), 34.8 (t, C-6), 33.7 (t,
C-12), 30.4 (t, C-7), 26.2 (t, C-16), 26.0 (t, C-11), 25.8 (t, C-1), 23.2
(t, C-15), 22.8 (t, C-2), 17.0 (q, C-18).
(Z)-19-Norandrost-4-ene-3,17-dione bis(thiosemicarbazone)
(3a-Z). 1H-NMR (500MHz, CDCl3): 0.83 (m, 1H, H-9), 0.94 (s, 3H,
H3C-18), 1.10 (m, 1H, Ha-7), 1.20 (m, 1H, H-14), 1.24–1.46 (m,
4H), 1.51 (m, 1H, Hb-15), 1.81–2.12 (m, 7H), 2.17–2.34 (m, 2H),
2.40 (dt, J ¼ 14.5, 3.5 Hz, 1H, Ha-2), 2.41–2.54 (m, 2H), 6.22 (s,
1H, H-4), 6.45 and 7.23 (2bs, 2H, NH2), 6.53 and 7.18 (2bs, 2H,
NH2), 8.49 (s, 1H, NH), 9.05 (s, 1H, NH).
13C NMR (125 MHz,
CDCl3): 178.7 (s, C]S), 178.2 (s, C]S), 167.0 (s, C-17), 158.4 (s,
C-5), 149.7 (s, C-3), 111.4 (d, C-4), 52.0 (d, C-14), 50.0 (d, C-9),
44.8 (s, C-13), 43.2 (d, C-10), 39.8 (d, C-8), 35.8 (t, C-6), 33.7 (t,
C-12), 30.2 (t, C-7), 26.2 (t, C-16), 26.0 (t, C-11), 25.7 (t, C-1), 23.2
(t, C-15), 22.8 (t, C-2), 17.0 (q, C-18).
Mixture of 2b (E/Z). Starting with 860 mg androst-4-ene-3,17-
dione (1b), elution with toluene/EtOAc (8/2) gave 2b (727 mg,
67.4%). Rf ¼ 0.60 (toluene/EtOAc, 6 : 4, double development).
Mp > 208 C (decomp.). IR (ATR/cm1): 3418 and 3252 (NH),
3149, 2939, 1731 (C]O), 1599, 1504 (C]N), 1266 (C]S), 735.RSC Adv., 2016, 6, 34312–34333 | 34323
Table 6 Antibacterial activity of compounds 2a–e, 3a–e, 4a–e and 5a–e
Comp.
Inhibition zone (mm)
E. coli P. hauseri P. aeruginosa S. enterica K. rhizophila C. sporogenes S. aureus B. subtilis
2a — — 10 10 12 10 — —
2b — 10 10 — 10 10 — —
2c — 10 10 — — 10 — —
2d — — — — — — — —
2e 10 12 12 12 12 12 10 12
3a — — — — — — — —
3b — — — — — — — —
3c — — — — — — — —
3d — — — — — — — —
3e — — — — — — — —
4a — — 10 — — 10 — —
4b 10 10 10 — 12 10 — —
4c — — 10 — 10 — 10 —
4d-OAc 10 10 12 12 10 12 12 10
4d-OH — — 10 — 10 — — —
4e — 10 — — 10 — — —
5a — — 10 10 10 10 — —
5b — 12 10 — 10 — — —
5c — 10 10 12 — 10 14 12
5d 10 10 — 10 10 10 — 12
5e — 10 10 10 10 — 14 —
Amikacin 42 24 20 24 22 20 32 22
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View Article OnlineESI-TOF-MS: m/z for C20H29N3OS [M + H]
+: calcd 360.21041,
found 360.21148.
(E)-Androst-4-ene-3,17-dione 3-thiosemicarbazone (2b-E).
1H-NMR (500 MHz, CDCl3): 0.91 (s, 3H, H3C-18), 1.05 (m, 1H,
Ha-7), 1.10 (s, 3H, H3C-19), 1.23–1.33 (m, 2H, H-14, Ha-12),Table 7 Antifungal activity of 2a–e, 3a–e, 4a–e and 5a–e
Comp.
Inhibition zone (mm)
C. albicans S. cerevisiae A. brasiliensis
2a — — 10
2b 10 — 12
2c — — 10
2d — — 10
2e 12 10 12
3a — — 10
3b — — 12
3c 12 12 10
3d — — 10
3e — — —
4a — — 12
4b 10 12 10
4c 10 10 9
4d-OAc 10 10 10
4d-OH 9 10 10
4e 9 9 10
5a — — 12
5b 12 10 10
5c — — 12
5d 10 12 10
5e 10 10 10
Nystatin 34 56 32
34324 | RSC Adv., 2016, 6, 34312–343331.40–1.50 (m, 2H, Hb-11, Ha-1), 1.56 (m, 1H, Hb-15), 1.62–1.76
(m, 2H, H-8, Ha-11), 1.82–2.03 (m, 4H, Hb-12, Hb-7, Ha-15, Hb-
1), 2.09 (dd, J ¼ 9.0, 19.0 Hz, 1H, Ha-16), 2.17 (m, 1H, Hb-2),
2.30–2.38 (m, 2H), 2.48 (J¼ 8.5, 19.0 Hz, 1H, Hb-16), 2.62 (dt, J¼
16.0, 3.5 Hz, 1H, Ha-2), 5.82 (s, 1H, H-4), 6.41 and 7.25 (bs and
m, 2H, NH2), 8.74 (s, 1H, NH).
13C NMR (125MHz, CDCl3): 220.5
(s, C-17), 178.3 (s, C]S), 157.9 (s, C-5), 150.1 (s, C-3), 120.5 (d, C-
4), 53.6 (d, C-9), 50.9 (d, C-14), 47.4 (s, C-13), 37.9 (s, C-10), 35.7
(t, C-16), 35.2 (d, C-8), 34.5 (t, C-1), 32.2 (t, C-6), 31.3 (t, C-12),
30.8 (t, C-7), 21.7 (t, C-15), 20.6 (2t, C-2 and C-11), 17.7 (q, C-
19), 13.6 (q, C-18).
(Z)-Androst-4-ene-3,17-dione 3-thiosemicarbazone (2b-Z).
1H-NMR (500 MHz, CDCl3): 0.91 (s, 3H, H3C-18), 1.05 (m, 1H,
Ha-7), 1.15 (s, 3H, H3C-19), 1.23–1.33 (m, 2H, H-14, Ha-12), 1.46
(m, 1H, Hb-11), 1.50 (m, 1H, Ha-1), 1.56 (m, 1H, Hb-15), 1.62–
1.76 (m, 2H, H-8, Ha-11), 1.82–2.03 (m, 4H, Hb-1, Hb-12, Ha-15,
Hb-7), 2.09 (dd, J ¼ 9.0, 19.0 Hz, 1H, Ha-16), 2.17 (m, 1H, Hb-2),
2.30–2.38 (m, 2H), 2.48 (J¼ 8.5, 19.0 Hz, 1H, Hb-16), 2.18 (dt, J¼
16.0, 3.5 Hz, 1H, Ha-2), 6.11 (s, 1H, H-4), 6.35 and 7.17 (bs and
m, 2H, NH2), 8.95 (s, 1H, NH).
13C NMR (125MHz, CDCl3): 220.4
(s, C-17), 178.4 (s, C]S), 163.0 (s, C-5), 148.9 (s, C-3), 110.3 (d, C-
4), 54.0 (d, C-9), 50.8 (d, C-14), 47.5 (s, C-13), 39.3 (s, C-10), 35.7
(t, C-16), 36.2 (t, C-1), 35.2 (d, C-8), 33.1 (t, C-6), 31.3 (t, C-12),
31.2 (t, C-7), 21.7 (t, C-15), 20.6 (t, C-11), 20.3 (t, C-2), 17.0
(q, C-19), 13.6 (q, C-18).
Further elution with toluene/EtOAc/MeOH (60/40/1) gave 3b
(79.4 mg, 6.1%).
Mixture of 3b (E/Z). Starting with 860 mg androst-4-ene-3,17-
dione (1b), elution with toluene/EtOAc (8/2) gave 2b (115.5 mg,
10.6%). Further elution with toluene/EtOAc/MeOH (60/40/1)This journal is © The Royal Society of Chemistry 2016
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View Article Onlineaﬀorded 3b (723 mg, 55.7%). Rf ¼ 0.22 (toluene/EtOAc, 6 : 4,
double development). Mp > 146 C (decomp.). IR (ATR/cm1):
3498 and 3272 (NH), 2941, 1565, 1487 (C]N), 1276 (C]S), 1080,
878. ESI-TOF-MS: m/z for C21H32N6S2 [M + H]
+: calcd 433.22026,
found 433.21908.
(E)-Androst-4-ene-3,17-dione bis(thiosemicarbazone) (3b-E).
1H-NMR (500 MHz, DMSO): 0.84 (s, 3H, H3C-18), 0.95 (m, 1H, H-
9), 1.04 (s, 3H, H3C-19), 1.20–1.32 (m, 2H), 1.33–1.45 (m, 2H),
1.51–1.67 (m, 2H), 1.74–1.96 (m, 4H), 2.17–2.43 (m, 4H), 2.53
(dd, J ¼ 9.0, 19.5 Hz, 1H, Hb-16), 2.79 (dt, J ¼ 17.0, 3.0 Hz, 1H,
Ha-2), 5.76 (s, 1H, H-4), 7.35 and 7.98 (2bs, 2H, NH2), 7.53 and
8.02 (2bs, 2H, NH2), 9.81 (s, 1H, NH), 10.03 (s, 1H, NH).
13C
NMR (125MHz, DMSO): 178.4 (s, C]S), 178.2 (s, C]S), 167.3 (s,
C-17), 156.5 (s, C-5), 150.6 (s, C-3), 120.8 (d, C-4), 53.4 (d, C-9),
52.4 (d, C-14), 44.2 (s, C-13), 37.4 (s, C-10), 34.7 (d, C-8), 34.4
(t, C-1), 33.6 (t, C-6), 31.7 (t, C-7), 31.3 (t, C-12), 26.8 (t, C-16), 23.1
(t, C-15), 21.0 (t, C-11), 20.5 (t, C-2), 17.4 (q, C-19), 16.8 (q, C-18).
(Z)-Androst-4-ene-3,17-dione bis(thiosemicarbazone) (3b-Z).
1H-NMR (500 MHz, DMSO): 0.84 (s, 3H, H3C-18), 0.95 (m, 1H, H-
9), 1.08 (s, 3H, H3C-19), 1.20–1.32 (m, 2H), 1.33–1.45 (m, 2H),
1.51–1.67 (m, 2H), 1.74–1.96 (m, 4H), 2.17–2.43 (m, 5H), 2.53
(dd, J ¼ 9.0, 19.5 Hz, 1H, Hb-16), 6.61 (s, 1H, H-4), 7.35 and 7.98
(2bs, 2H, NH2), 7.50 and 7.93 (2bs, 2H, NH2), 9.81 (s, 1H, NH),
10.34 (s, 1H, NH). 13C NMR (125 MHz, DMSO): 178.4 (s, C]S),
178.3 (s, C]S), 167.3 (s, C-17), 160.6 (s, C-5), 148.0 (s, C-3), 112.2
(d, C-4), 53.7 (d, C-14), 52.3 (d, C-9), 44.3 (s, C-13), 38.5 (s, C-10),
36.1 (t, C-1), 34.6 (d, C-8), 33.5 (t, C-6), 32.2 (t, C-7), 31.3 (t, C-12),
26.8 (t, C-16), 23.1 (t, C-15), 21.0 (t, C-11), 20.2 (t, C-2), 17.7 (q, C-
19), 16.8 (q, C-18).
Mixture of 2c (E/Z). Starting with 860 mg androsta-4,9(11)-
diene-3,17-dione (1c), elution with toluene/EtOAc (85/15) gave
2c (430 mg, 39.9%). Rf ¼ 0.44 (toluene/EtOAc, 6 : 4, double
development). Mp > 198 C (decomp.). IR (ATR/cm1): 3425 and
3256 (NH), 3142, 2928, 1737 (C]O), 1585, 1502 (C]N), 1297
(C]S), 1087, 877. ESI-TOF-MS: m/z for C20H27N3OS [M + H]
+:
calcd 358.19476, found 358.19350.
(E)-Androsta-4,9(11)-diene-3,17-dione 3-thiosemicarbazone
(2c-E). 1H-NMR (200 MHz, DMSO): 0.79 (s, 3H, H3C-18), 0.98 (m,
1H, Ha-7), 1.21 (s, 3H, H3C-19), 2.88 (br.d, J ¼ 17.4 Hz, 1H, Ha-
2), 5.49 (br.s, 1H, H-11), 5.81 (s, 1H, H-4), 7.56 and 8.09 (bs and
m, 2H, NH2), 10.11 (s, 1H, NH).
13C NMR (50 MHz, DMSO):
220.7 (s, C-17), 178.5 (s, C]S), 154.8 (s, C-5), 150.4 (s, C-3), 146.4
(s, C-9), 121.3 (d, C-4), 116.8 (d, C-11), 47.6 (d, C-14), 45.5 (s, C-
13), 40.4 (s, C-10, overlapped by DMSO), 36.7 (t, C-16), 36.1 (d, C-
8), 33.3 (t, C-1), 32.8 (t, C-12), 31.8 (t, C-6), 31.3 (t, C-7), 26.4 (q, C-
19), 22.5 (t, C-15), 21.5 (t, C-2), 13.8 (q, C-18).
(Z)-Androsta-4,9(11)-diene-3,17-dione 3-thiosemicarbazone
(2c-Z). 1H-NMR (200 MHz, DMSO): 0.79 (s, 3H, H3C-18), 0.98 (m,
1H, Ha-7), 1.26 (s, 3H, H3C-19), 5.49 (br.s, 1H, H-11), 6.65 (s, 1H,
H-4), 7.56 and 8.00 (bs and m, 2H, NH2), 10.38 (s, 1H, NH).
13C
NMR (50 MHz, DMSO): 220.7 (s, C-17), 178.3 (s, C]S), 158.9 (s,
C-5), 147.8 (s, C-3), 146.4 (s, C-9), 121.3 (d, C-4), 116.8 (d, C-11),
47.6 (d, C-14), 45.5 (s, C-13), 41.3 (s, C-10), 36.7 (t, C-16), 36.5 (d,
C-8), 33.4 (t, C-1), 32.8 (t, C-12), 31.8 (t, C-6), 31.3 (t, C-7), 26.7 (q,
C-19), 22.5 (t, C-15), 20.4 (t, C-2), 13.8 (q, C-18).
Further elution with toluene/EtOAc/MeOH (60/40/1) gave 3c
(77.4 mg, 5.9%).This journal is © The Royal Society of Chemistry 2016Mixture of 3c (E/Z). Starting with 860 mg androsta-4,9(11)-
diene-3,17-dione (1c), elution with toluene/EtOAc (85/15) gave
2c (115.5 mg, 10.6%). Further elution with toluene/EtOAc/
MeOH (85/15/2) aﬀorded 3c (723 mg, 55%). Rf ¼ 0.56 (CHCl3/
MeOH, 95 : 5, double development). Mp > 146 C (decomp.). IR
(ATR/cm1): 3503, 3359, 3257, 3148 (NH), 2941, 1587, 1501 (C]
N), 1280 (C]S), 1088, 753. ESI-TOF-MS:m/z for C21H30N6S2 [M +
H]+: calcd 431.20461, found 431.20339.
(E)-Androsta-4,9(11)-diene-3,17-dione bis(thiosemicarbazone)
(3c-E). 1H-NMR (200 MHz, DMSO): 0.82 (s, 3H, H3C-18), 1.19 (s,
3H, H3C-19), 2.88 (d, J¼ 16.0 Hz, 1H, Ha-2), 5.51 (br.s, 1H, H-11),
5.80 (s, 1H, H-4), 7.42 and 8.07 (bs andm, 2H, NH2), 7.57 and 8.07
(2bs, 2H, NH2), 9.89 (s, 1H, NH), 10.09 (s, 1H, NH).
13C NMR (50
MHz, DMSO): 178.6 (s, C]S), 178.5 (s, C]S), 167.3 (s, C-17),
155.1 (s, C-5), 150.5 (s, C-3), 146.1 (s, C-9), 121.2 (d, C-4), 117.4
(d, C-11), 49.7 (d, C-14), 43.0 (s, C-13), 40.1 (s, C-10), 36.6 (t, C-12),
36.2 (d, C-8), 32.8 (t, C-1), 31.9 (t, C-6), 31.8 (t, C-7), 27.5 (t, C-16),
26.4 (q, C-19), 24.3 (t, C-15), 21.5 (t, C-2), 17.2 (q, C-18).
(Z)-Androsta-4,9(11)-diene-3,17-dione bis(thiosemicarba-
zone) (3c-Z). 1H-NMR (200 MHz, DMSO): 0.82 (s, 3H, H3C-18),
1.25 (s, 3H, H3C-19), 5.51 (br.s, 1H, H-11), 6.64 (s, 1H, H-4),
7.42 and 8.07 (2bs, 2H, NH2), 7.57 and 8.00 (2bs, 2H, NH2),
9.89 (s, 1H, NH), 10.38 (s, 1H, NH). 13C NMR (50 MHz, DMSO):
178.6 (s, C]S), 178.3 (s, C]S), 167.3 (s, C-17), 159.1 (s, C-5),
147.9 (s, C-3), 146.1 (s, C-9), 117.4 (d, C-11), 113.0 (d, C-4),
49.7 (d, C-14), 43.0 (s, C-13), 41.3 (s, C-10), 36.6 (t, C-12), 36.3
(d, C-8), 34.4 (t, C-1), 31.9 (t, C-6), 31.8 (t, C-7), 27.5 (t, C-16), 26.5
(q, C-19), 24.3 (t, C-15), 22.5 (t, C-2), 17.2 (q, C-18).
Mixture of 2d (E/Z). Starting with 910mg 11a-hydroxyandrost-4-
ene-3,17-dione (1d), elution with toluene/EtOAc/MeOH (50/50/0.1)
gave 2d (876 mg, 78.2%). Rf¼ 0.53 (CHCl3/MeOH, 9 : 1). Mp > 218
C (decomp.). IR (ATR/cm1): 3419 and 3257 (NH), 2927, 1736 (C]
O), 1587, 1503 (C]N), 1024 (C]S), 737. ESI-TOF-MS: m/z for
C20H29N3O2S [M + H]
+: calcd 376.20532, found 376.20446; m/z for
C20H29N3O2S [M + Na]
+: calcd 398.18727, found 398.18694:m/z for
C20H29N3O2S [M + K]
+: calcd 414.16121, found 414.16159.
(E)-11a-Hydroxyandrost-4-ene-3,17-dione 3-thiosemicarbazone
(2d-E). 1H-NMR (200 MHz, CDCl3/CD3OD): 0.95 (s, 3H, H3C-18),
1.24 (s, 3H, H3C-19), 3.97 (dt, J ¼ 4.5, 10.2 Hz, 1H, Hb-11), 5.85
(s, 1H, H-4), 7.24 and 7.39 (2m, 2H, NH2), 9.31 (s, 1H, NH).
13C
NMR (50 MHz, CDCl3/CD3OD): 220.8 (s, C-17), 177.3 (s, C]S),
158.2 (s, C-3), 151.4 (s, C-5), 120.8 (d, C-4), 67.8 (d, C-11), 58.4 (d, C-
9), 49.8 (d, C-14), 47.8 (s, C-13), 41.7 (t, C-12), 38.9 (s, C-10), 35.5 (t,
C-16), 35.4 (d, C-8), 34.4 (t, C-1), 32.8 (t, C-6), 30.1 (t, C-7), 21.3 (t, C-
15), 20.5 (t, C-2), 18.0 (q, C-19), 14.1 (q, C-18).
(Z)-11a-Hydroxyandrost-4-ene-3,17-dione 3-thiosemicarbazone
(2d-Z). 1H-NMR (200 MHz, CDCl3/CD3OD): 0.95 (s, 3H, H3C-18),
1.29 (s, 3H, H3C-19), 3.97 (dt, J ¼ 4.5, 10.2 Hz, 1H, Hb-11), 6.22
(s, 1H, H-4), 7.24 and 7.35 (2m, 2H, NH2), 9.55 (s, 1H, NH).
13C
NMR (50 MHz, CDCl3/CD3OD): 220.4 (s, C-17), 177.2 (s, C]S),
162.8 (s, C-3), 150.3 (s, C-5), 112.2 (d, C-4), 67.8 (d, C-11), 58.4 (d, C-
9), 49.7 (d, C-14), 47.1 (s, C-13), 41.7 (t, C-12), 40.2 (s, C-10), 35.5 (t,
C-16), 37.4 (d, C-8), 34.2 (t, C-1), 33.5 (t, C-6), 30.5 (t, C-7), 21.3 (t, C-
15), 21.3 (t, C-2), 18.3 (q, C-19), 14.1 (q, C-18).
Further elution with toluene/EtOAc/MeOH (50/50/2) gave 3d
(88 mg, 10%).RSC Adv., 2016, 6, 34312–34333 | 34325
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View Article OnlineMixture of 3d (E/Z). Starting with 910 mg 11a-
hydroxyandrost-4-ene-3,17-dione (1d), elution with toluene/
EtOAc/MeOH (50/50/0.1) gave 2d (151 mg, 13.3%). Further
elution with toluene/EtOAc/MeOH (50/50/2) aﬀorded 3d (640
mg, 47.6%). Rf ¼ 0.40 (CHCl3/MeOH, 9 : 1). Mp > 176 C
(decomp.). IR (ATR/cm1): 3510 and 3414 (NH), 2925, 1586,
1501 (C]N), 1299, 1086, 867. ESI-TOF-MS:m/z for C21H32N6OS2:
[M + H]+: calcd 449.21518, found 449.21447.
(E)-11a-Hydroxyandrost-4-ene-3,17-dione bis(thiosemicarba-
zone) (3d-E). 1H-NMR (200 MHz, CDCl3/CD3OD): 0.96 (s, 3H,
H3C-18), 1.24 (s, 3H, H3C-19), 3.90 (overlapped with CD3OD, 1H,
Hb-11), 5.84 (s, 1H, H-4), 7.19 and 7.38 (2m, 4H, NH2), 8.89 (s,
1H, NH), 9.28 (s, 1H, NH). 13C NMR (50 MHz, CDCl3/CD3OD):
177.8 (s, C]S), 177.3 (s, C]S), 166.5 (s, C-17), 158.1 (s, C-3),
151.5 (s, C-5), 120.9 (d, C-4), 68.0 (d, C-11), 58.6 (d, C-9), 51.8
(d, C-14), 44.7 (t, C-12), 44.3 (s, C-13), 38.9 (s, C-10), 35.5 (d, C-8),
34.4 (t, C-1), 32.8 (t, C-6), 30.8 (t, C-7), 25.9 (t, C-16), 23.0 (t, C-15),
20.6 (t, C-2), 18.1 (q, C-19), 17.4 (q, C-18).
(Z)-11a-Hydroxyandrost-4-ene-3,17-dione bis(thiosemicarba-
zone) (3d-Z). 1H-NMR (200 MHz, CDCl3/CD3OD): 0.96 (s, 3H,
H3C-18), 1.29 (s, 3H, H3C-19), 3.70 (m, 1H, Hb-11), 6.20 (s, 1H, H-
4), 7.19 and 7.38 (2m, 4H, NH2), 8.89 (s, 1H, NH), 9.51 (s, 1H,
NH). 13C NMR (50 MHz, CDCl3/CD3OD): 177.8 (s, C]S), 177.3 (s,
C]S), 166.5 (s, C-17), 162.9 (s, C-3), 150.3 (s, C-5), 111.2 (d, C-4),
68.0 (d, C-11), 59.0 (d, C-9), 51.7 (d, C-14), 44.7 (t, C-12), 44.3 (s, C-
13), 40.3 (s, C-10), 37.5 (d, C-8), 34.2 (t, C-1), 33.6 (t, C-6), 31.2 (t,
C-7), 25.9 (t, C-16), 23.0 (t, C-15), 21.4 (t, C-2), 18.4 (q, C-19), 17.4
(q, C-18).
Mixture of 2e (E/Z). Starting with 940 mg progesterone (1e),
aer ltration the product was recrystallized from ethanol to
aﬀord light yellow crystals of 2e (765 mg, 65%). Rf ¼ 0.48
(toluene/EtOAc, 6 : 4, double development). Mp > 200 C
(decomp.). IR (ATR/cm1): 3430, 3328 (NH), 2939, 1696 (C]O),
1589, 1503 (C]N), 1291 (C]S), 1048, 735. ESI-TOF-MS: m/z for
C22H33N3OS [M + H]
+: calcd 388.24171, found 388.24102;m/z for
C22H33N3OS [M + Na]
+: calcd 410.22365, found 410.22379.
(E)-Pregn-4-ene-3,20-dione 3-thiosemicarbazone (2e-E). 1H-
NMR (200 MHz, CDCl3/CD3OD): 0.66 (s, 3H, H3C-18), 1.09 (s,
3H, H3C-19), 2.14 (s, 3H, H3C-21), 2.32 (dt, J ¼ 15.4, 3.6 Hz, 1H,
Ha-2), 2.55 (t, J ¼ 9.0 Hz, 1H, Ha-17), 5.81 (s, 1H, H-4), 6.88 and
7.30 (2m, 2H, NH2), 9.15 (s, 1H, NH).
13C NMR (50 MHz, CDCl3):
210.3 (s, C-20), 177.4 (s, C]S), 158.3 (s, C-5), 150.8 (s, C-3), 120.1
(d, C-4), 63.4 (d, C-17), 55.9 (d, C-14), 53.2 (d, C-9), 43.8 (s, C-13),
38.5 (s, C-10), 37.6 (t, C-12), 35.5 (d, C-8), 34.4 (t, C-1), 32.2 (t, C-
6), 31.8 (t, C-7), 31.3 (q, C-21), 24.2 (t, C-16), 22.6 (t, C-15), 21.1 (t,
C-11), 20.4 (t, C-2), 17.6 (q, C-19), 13.1 (q, C-18).
(Z)-Pregn-4-ene-3,20-dione 3-thiosemicarbazone (2e-Z). 1H-
NMR (200 MHz, CDCl3/CD3OD): 0.66 (s, 3H, H3C-18), 1.13 (s,
3H, H3C-19), 2.14 (s, 3H, H3C-21), 2.55 (t, J¼ 9.0 Hz, 1H, Ha-17),
6.15 (s, 1H, H-4), 6.82 and 7.19 (2m, 2H, NH2), 9.40 (s, 1H, NH).
13C NMR (50 MHz, CDCl3): 210.3 (s, C-20), 177.6 (s, C]S), 163.5
(s, C-5), 149.7 (s, C-3), 110.2 (d, C-4), 63.4 (d, C-17), 55.9 (d, C-14),
53.7 (d, C-9), 43.8 (s, C-13), 39.0 (s, C-10), 37.6 (t, C-12), 36.1 (d,
C-8), 34.4 (t, C-1), 33.2 (t, C-6), 31.8 (t, C-7), 31.3 (q, C-21), 24.2 (t,
C-16), 22.6 (t, C-15), 21.1 (t, C-11), 20.9 (t, C-2), 17.4 (q, C-19),
13.1 (q, C-18).34326 | RSC Adv., 2016, 6, 34312–34333The residue aer crystallization was chromatographed by
FCC. Elution with toluene/EtOAc/MeOH (50/50/1) aﬀorded 3e
(114 mg, 8.3%).
Mixture of 3e (E/Z). Starting with 940 mg progesterone (1e),
aer ltration the product was recrystallized from ethanol.
Yellow crystals (808 mg, 59%) were obtained as a mixture of two
diastereoisomers, E and Z (4 : 1), which could not be separated.
Rf ¼ 0.29 (toluene/EtOAc, 6 : 4, double development). Mp >
201 C (decomp.). IR (ATR/cm1): 3427, 3374, 3232, 3146 (NH),
2938, 1590, 1507 (C]N), 1296 (C]S), 1108, 866. Anal. calcd for
C23H36N6S2: C 59.96; H 7.88; N 18.24; S 13.92. Found: C 59.64; H
7.69; N 17.97; S 13.87. ESI-TOF-MS:m/z for C23H36N6S2 [M + H]
+:
calcd 461.25156, found 461.25130.
(E)-Pregn-4-ene-3,20-dione bis(thiosemicarbazone) (3e-E).
1H-NMR (500 MHz, DMSO): 0.55 (s, 3H, H3C-18), 0.82 (m, 1H, H-
9), 0.90 (m, 1H, Ha-7), 1.00 (s, 3H, H3C-19), 1.08–1.19 (m, 2H, H-
14, Ha-15), 1.25–1.39 (m, 3H, Ha-1, Hb-11, Hb-12), 1.44 (br.d, J
¼ 10.5 Hz, 1H, H-8), 1.48–1.56 (m, 2H, Ha-11, Ha-16), 1.60 (t, J¼
7.0 Hz, 1H, Hb-15), 1.73 (m, 1H, Hb-7), 1.79 (m, 1H, Ha-12), 1.88
(s, 3H, H3C-21), 2.05–2.20 (2m, 2H, Hb-2, Ha-6), 2.24–2.34 (m,
3H, Hb-6, Hb-16, Ha-17), 2.80 (br.d, J ¼ 17.6 Hz, 1H, Ha-2), 5.75
(s, 1H, H-4), 7.38 and 8.07 (2bs, 2H, NH2), 7.52 and 8.04 (2bs,
2H, NH2), 9.79 (s, 1H, NH), 10.04 (s, 1H, NH).
13C NMR (125
MHz, DMSO): 178.5 (s, C]S), 178.3 (s, C]S), 156.4 (s, C-5),
153.9 (s, C-20), 150.4 (s, C-3), 120.7 (d, C-4), 58.38 (d, C-17),
55.2 (d, C-14), 53.2 (d, C-9), 43.6 (s, C-13), 38.2 (t, C-12), 37.2
(s, C-10), 35.5 (d, C-8), 34.5 (t, C-1), 31.8 (t, C-6), 31.8 (t, C-7), 23.8
(t, C-15), 22.7 (t, C-16), 21.0 (t, C-11), 20.9 (t, C-2), 18.4 (q, C-21),
17.4 (q, C-19), 13.1 (q, C-18).
(Z)-Pregn-4-ene-3,20-dione bis(thiosemicarbazone) (3e-Z).
1H-NMR (500 MHz, DMSO): 0.55 (s, 3H, H3C-18), 0.82 (m, 1H, H-
9), 0.90 (m, 1H, Ha-7), 1.06 (s, 3H, H3C-19), 1.13 (m, 2H, H-14,
Ha-15), 1.32 (m, 3H, Ha-1, Hb-11, Hb-12), 1.44 (br.d, J ¼ 10.5
Hz, 1H, H-8), 1.52 (m, 2H, Ha-11, Ha-16), 1.60 (t, J ¼ 7.0 Hz, 1H,
Hb-15), 1.73 (m, 1H, Hb-7), 1.79 (m, 1H, Ha-12), 1.88 (s, 3H,
H3C-21), 2.04–2.22 (2m, 2H, Hb-2, Ha-16), 2.24–2.37 (m, 3H, Hb-
6, Hb-16, Ha-17), 6.61 (s, 1H, H-4), 7.38 and 8.07 (2bs, 2H, NH2),
7.50 and 7.94 (2bs, 2H, NH2), 9.79 (s, 1H, NH), 10.33 (s, 1H, NH).
13C NMR (125 MHz, DMSO): 178.5 (s, C]S), 178.0 (s, C]S),
160.7 (s, C-5), 154.9 (s, C-20), 147.8 (s, C-3), 112.1 (d, C-4), 58.34
(d, C-17), 55.1 (d, C-14), 53.6 (d, C-9), 43.5 (s, C-13), 38.1 (t, C-12),
38.3 (s, C-10), 36.0 (t, C-1), 35.4 (d, C-8), 32.3 (t, C-6), 32.2 (t, C-7),
23.8 (t, C-15), 22.7 (t, C-16), 21.0 (t, C-11), 20.8 (t, C-2), 18.4 (q, C-
21), 17.6 (q, C-19), 13.1 (q, C-18).
The residue aer crystallization was chromatographed by
FCC. Elution with toluene/EtOAc (70/30) aﬀorded 2e (86 mg,
7.4%).General procedure for the synthesis of thiadiazolines
Thiadiazolines 4a–e and 5a–e were prepared according to the
literature.21 To a stirred solution of steroidal thio-
semicarbazones 2a–e and 3a–e (1 mmol) in chloroform (25 mL),
freshly distilled acetic anhydride (2.3 and 4.6 mL, respectively)
and pyridine (1.2 and 2.4 mL, respectively) were added. The
reaction mixture was stirred for 4 h over an oil bath at 85 C and
monitored by TLC. Aer completion of the reaction, the solventThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinewas removed under reduced pressure. The residue was chro-
matographed by FCC (the eluents and the ratio are mentioned
in each experiment).
(3R)-N-(30-Acetyl-17-oxospiro[19-norandrost-4-ene-3,20-[1,3,4]
thiadiazoline]-50-yl)acetamide (4a). Starting with 340 mg of the
mixture of 2a, elution with toluene/EtOAc (5/5) and crystalliza-
tion from DMSO gave 4a (285 mg, 67%). Rf ¼ 0.45 (CHCl3/
CH3OH, 95 : 5, double development). Mp. 194.5–195.4 C; [a]D
+58 (c 1.0  103 in CHCl3/CH3OH (3 : 1)); IR (ATR/cm1): 2928
(C–H), 1736 (C]O), 1618 (C]N), 1410 (C]N), 756 (C]S); 1H-
NMR (500 MHz, CDCl3/CD3OD): 0.66 (m, 1H, H-9), 0.91 (s, 3H,
H3C-18), 0.99 (m, 1H, Ha-7), 1.16–1.47 (m, 5H), 1.56 (m, 1H, Hb-
15), 1.74–2.00 (m, 5H), 2.04–2.16 (m, 4H overlapped with C(50)-
NHCOCH3), 2.11 (s, 3H, C(50)-NHCOCH3), 2.19 (s, 3H, N(30)-
COCH3), 2.32 (dt, J ¼ 14.5, 3.0 Hz, 1H, Hb-6), 2.46 (dd, J ¼ 19.5,
8.5 Hz, 1H, Hb-16), 2.59 (td, J ¼ 13.5, 2.5 Hz, 1H, Ha-2), 5.67 (s,
1H, H-4), 10.57 (s, 1H, NH). 13C NMR (125MHz, CDCl3): 222.4 (s,
C-17), 169.6 (s, C(50)-NHCOCH3), 169.2 (s, N(30)-COCH3), 144.5
(s, C-50), 141.1 (s, C-5), 121.6 (d, C-4), 79.9 (s, C-3), 50.1 (d, C-9),
50.0 (d, C-14), 47.8 (s, C-13), 40.3 (d, C-10), 39.8 (d, C-8), 35.6 (t,
C-16), 34.1 (t, C-6), 33.4 (t, C-2), 31.1 (t, C-12), 29.8 (t, C-7), 25.8 (t,
C-11), 25.1 (t, C-1), 23.3 (q, COCH3), 22.4 (q, NHCOCH3), 21.4 (t,
C-15), 13.5 (q, C-18). Anal. calcd for C23H31N3O3S  0.5CH3-
SOCH3: C 61.51; H 7.31; N 8.97; S 10.26. Found: C 61.18; H 7.16;
N 8.99; S 10.85. ESI-TOF-MS: m/z for C23H31N3O3S [M + H]
+:
calcd 430.21589, found 430.21581; m/z for C23H31N3O3S [M +
Na]+: calcd 452.19783, found 452.19790.
(3R)-N-(30-Acetyl-17-oxospiro[androst-4-ene-3,20-[1,3,4]thia-
diazoline]-50-yl)acetamide (4b). Starting with 360 mg of the
mixture of 2b, elution with toluene/EtOAc (5/5) gave 4b (321 mg,
73%). Rf ¼ 0.58 (CHCl3/CH3OH, 95 : 5, double development).
Mp. 222.1–222.8 C; [a]D +109 (c 1.05  103 in CHCl3/CH3OH
(3 : 1)); IR (ATR/cm1): 3233, 2948 (C–H), 2926, 1710 (C]O),
1661 (C]N), 1386 (C]N); 1H-NMR (500 MHz, CDCl3/CD3OD):
0.80 (td, J ¼ 3.5, 12.5 Hz, 1H, H-9), 0.90 (s, 3H, H3C-18), 0.95 (m,
1H, Ha-7), 1.12 (s, 3H, H3C-19), 1.20–1.32 (m, 2H, Ha-12, H-14),
1.39 (dq, J¼ 13.0, 3.0 Hz, 1H, Ha-11), 1.53 (m, 2H, Ha-1, Hb-15),
1.60–1.68 (m, 2H, H-8, Ha-11), 1.78–1.89 (m, 3H, Hb-1, Hb-7,
Hb-12), 1.96 (m, 1H, Hb-15), 2.03 (br.d, J ¼ 13.5 Hz, 1H, Hb-2),
2.09–2.12 (m, 2H, Ha-6, Ha-16, overlapped with C(50)-
NHCOCH3), 2.11 (s, 3H, C(50)-NHCOCH3), 2.19 (s, 3H, N(30)-
COCH3), 2.32 (dt, J ¼ 14.5, 3.0 Hz, 1H, Hb-6), 2.60 (dd, J ¼ 19.5,
8.5 Hz, 1H, Hb-16), 2.80 (td, J ¼ 14.0, 2.5 Hz, 1H, Ha-2), 5.54 (s,
1H, H-4), 10.50 (s, 1H, NH). 13C NMR (125 MHz, CDCl3/CD3OD):
222.2 (s, C-17), 169.5 (s, C(50)-NHCOCH3), 169.2 (s, N(30)-
COCH3), 145.4 (s, C-50), 144.4 (s, C-5), 120.6 (d, C-4), 80.1 (s, C-3),
54.1 (d, C-9), 50.8 (d, C-14), 47.6 (s, C-13), 36.7 (s, C-10), 35.7 (t,
C-16), 35.2 (d, C-8), 35.1 (t, C-1), 31.4 (t, C-6), 31.1 (t, C-12), 30.9
(t, C-7), 30.8 (t, C-2), 25.8 (t, C-11), 23.2 (q, COCH3), 22.5 (q,
NHCOCH3), 21.5 (t, C-15), 17.4 (q, C-19), 13.5 (q, C-18). ESI-TOF-
MS: m/z for C24H33N3O3S [M + H]
+: calcd 444.23154, found
444.23112; m/z for C24H33N3O3S [M + Na]
+: calcd 466.21348,
found 466.21310.
(3R)-N-(30-Acetyl-17-oxospiro[androsta-4,9(11)-diene-3,20-
[1,3,4]thiadiazoline]-50-yl)acetamide (4c). Starting with 360 mg
of the mixture of 2c, elution with toluene/EtOAc (5/5) gave 4c
(318 mg, 72%). Rf ¼ 0.35 (toluene/EtOAc, 6 : 4, doubleThis journal is © The Royal Society of Chemistry 2016development). Mp. 219.1–220.2 C; [a]D +135 (c 1.01  103 in
CHCl3); IR (ATR/cm
1): 3216, 3075, 2928 (C–H), 1738 (C]O),
1612 (C]N), 1411 (C]N), 1240, 1035, 754; 1H-NMR (500 MHz,
CDCl3): 0.84 (s, 3H, H3C-18), 1.01 (dq, J ¼ 4.0, 12.5 Hz, 1H, Ha-
7), 1.25 (s, 3H, H3C-19), 1.48 (m, 1H, H-14), 1.57 (m, 1H, Hb-15),
1.87 (td, J ¼ 3.0, 13.5 Hz, 1H, Ha-1), 2.15 (s, 3H, C(50)-
NHCOCH3), 2.21 (s, 3H, N(30)-COCH3), 2.27 (t, J ¼ 11 Hz, 1H, H-
8), 2.36 (t, J ¼ 13 Hz, 1H, Hb-6), 2.47 (dd, J ¼ 18.5, 9.0 Hz, 1H,
Hb-16), 2.90 (t, J¼ 13.5 Hz, 1H, Ha-2), 5.44 (d, J¼ 6.0 Hz, 1H, H-
11), 5.56 (s, 1H, H-4), 9.65 (s, 1H, NH). 13C NMR (125 MHz,
CDCl3): 221.9 (s, C-17), 169.2 (s, N(30)-COCH3), 168.9 (s, C(50)-
NHCOCH3), 144.8 (s, C-50), 146.4 (s, C-9), 144.0 (s, C-5), 120.9 (d,
C-4), 116.9 (d, C-11), 80.3 (s, C-3), 48.0 (d, C-14), 45.9 (s, C-13),
39.4 (d, C-10), 36.9 (t, C-16), 36.2 (d, C-8), 33.2 (t, C-1), 33.0 (t,
C-12), 31.8 (t, C-6), 30.9 (t, C-7), 31.5 (t, C-2), 26.4 (q, C-19), 23.7
(q, COCH3), 23.1 (q, NHCOCH3), 22.7 (t, C-15), 13.9 (q, C-18).
ESI-TOF-MS: m/z for C24H31N3O3S [M + H]
+: calcd 442.21589,
found 442.21584; m/z for C24H31N3O3S [M + Na]
+: calcd
464.19783, found 464.19803.
(3R)-N-(11a-Acetoxy-30-acetyl-17-oxospiro[androst-4-ene-3,20-
[1,3,4]thiadiazoline]-50-yl)acetamide (4d-OAc). Starting with 375
mg of the mixture of 2d, elution with toluene/EtOAc (65/35) gave
4d-OAc (335 mg, 67%). Rf ¼ 0.60 (CHCl3/CH3OH, 9 : 1). Mp.
162.3–164.8 C; [a]D +90 (c 0.97  103 in CHCl3); IR (ATR/
cm1): 3235, 3174, 2971, 2935 (C–H), 1730 (C]O), 1703, 1642,
1613 (C]N), 1390 (C]N), 1240, 733; 1H-NMR (500 MHz,
CDCl3): 0.96 (s, 3H, H3C-18), 1.05 (dq, J ¼ 4.0, 14.0 Hz, 1H, Ha-
7), 1.17 (s, 3H, H3C-19), 1.22–1.31 (m, 2H, H-9, Ha-12), 1.40 (m,
1H, H-14), 1.55 (m, 1H, Hb-15), 1.66–1.74 (m, 2H, Ha-1, H-8),
1.82–1.91 (m, 2H, Hb-1, Hb-7), 1.93–1.99 (m, 2H, Hb-2, Ha-
15), 2.01 (s, 3H, OCOCH3-11), 2.16 (s, 3H, C(50)-NHCOCH3), 2.21
(s, 3H, N(30)-COCH3), 2.49 (dd, J ¼ 19.0, 9.0 Hz, 1H, Hb-16), 2.78
(td, J ¼ 13.5, 2.5 Hz, 1H, Ha-2), 5.22 (m, 1H, Hb-11), 5.64 (s, 1H,
H-4), 9.83 (s, 1H, NH). 13C NMR (125 MHz, CDCl3): 218.5 (s, C-
17), 169.2 (s, OCOCH3), 169.2 (2s, N(30)-COCH3 and C(50)-
NHCOCH3), 144.6 (s, C-50), 144.1 (s, C-5), 122.5 (d, C-4), 79.5 (s,
C-3), 70.5 (d, C-11), 56.4 (d, C-9), 49.6 (d, C-14), 47.4 (s, C-13),
38.2 (d, C-10), 38.1 (t, C-12), 35.7 (t, C-1), 35.6 (t, C-16), 34.8
(d, C-8), 32.3 (t, C-6), 31.0 (t, C-2), 30.7 (t, C-7), 23.6 (q, COCH3),
23.0 (q, NHCOCH3), 21.8 (q, OCOCH3), 21.6 (t, C-15), 18.4 (q, C-
19), 14.2 (q, C-18). ESI-TOF-MS: m/z for C26H35N3O5S [M + H]
+:
calcd 502.23702, found 502.23678; m/z for C26H35N3O5S [M +
Na]+: calcd 524.21896, found 524.21936.
Further elution with toluene/EtOAc/MeOH (50/50/4) gave
(3R)-N-(30-acetyl-11a-hydroxy-17-oxospiro[androst-4-ene-3,20-
[1,3,4]thiadiazoline]-50-yl)acetamide (4d-OH) (38 mg, 8%). Rf ¼
0.45 (CHCl3/CH3OH, 9 : 1). Mp. 215.8–220.0 C; [a]D +102 (c 0.96
 103 in CHCl3/CH3OH (3 : 1)); IR (ATR/cm1): 3518, 3320,
2927 (C–H), 1717 (C]O), 1690, 1663, 1605 (C]N), 1377 (C]N),
1238, 1012, 721; 1H-NMR (500 MHz, CDCl3/CD3OD): 0.93 (s, 3H,
H3C-18), 0.97 (m, 1H, H-9), 1.00 (m, 1H, Ha-7), 1.26 (s, 3H, H3C-
19), 1.31 (m, 1H, Ha-12), 1.39 (m, 1H, H-14), 1.51–1.66 (m, 2H,
H-8, Hb-15), 1.74 (t, J ¼ 13.5 Hz, 1H, Ha-1), 1.85 (m, 1H, Hb-7),
1.97 (m, 2H, Hb-2, Ha-15), 2.05 (m, 1H, Hb-12), 2.10 (s, 3H,
C(50)-NHCOCH3), 2.20 (s, 3H, N(30)-COCH3), 2.26 (m, 1H, H-6),
2.49 (dd, J ¼ 19.0, 9.0 Hz, 1H, Hb-16), 2.55 (dt, J ¼ 13.5, 3 Hz,
1H, Hb-1), 2.84 (td, J¼ 13.5, 2.5 Hz, 1H, Ha-2), 3.95 (td, J¼ 10.5,RSC Adv., 2016, 6, 34312–34333 | 34327
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View Article Online5 Hz, 1H, Hb-11), 5.57 (s, 1H, H-4). 13C NMR (125 MHz, CDCl3/
CD3OD (3 : 1)): 220.7 (s, C-17), 169.1 (2s, N(30)-COCH3 and C(50)-
NHCOCH3), 145.2 (s, C-5), 144.6 (s, C-50), 121.5 (d, C-4), 79.8 (s,
C-3), 68.1 (d, C-11), 59.5 (d, C-9), 49.9 (d, C-14), 47.8 (s, C-13),
41.9 (t, C-12), 37.9 (d, C-10), 36.6 (t, C-1), 35.6 (t, C-16), 34.8
(d, C-8), 32.2 (t, C-6), 30.8 (t, C-2), 30.3 (t, C-7), 23.1 (q,
NHCOCH3), 22.2 (q, OCOCH3), 21.4 (t, C-15), 17.7 (q, C-19), 14.2
(q, C-18). ESI-TOF-MS: m/z for C24H33N3O5S [M + H]
+: calcd
460.22645, found 460.22563; m/z for C24H33N3O5S [M + Na]
+:
calcd 482.20840, found 482.20780.
(3R)-N-(30-Acetyl-20-oxospiro[pregn-4-ene-3,20-[1,3,4]thiadia-
zoline]-50-yl)acetamide (4e). Starting with 387 mg of the mixture
of 2e, aer evaporation of the solvent the product was crystal-
lized from a mixture of CHCl3/MeOH to give pure 4e (363 mg,
77%). Rf¼ 0.40 (toluene/EtOAc, 6 : 4, double development). Mp.
213.4–214.9 C; [a]D +108 (c 1.03  103 in CHCl3/CH3OH
(3 : 1)). IR (ATR/cm1): 3229, 3169, 2929, 2846 (C–H), 1693 (C]
O), 1657, 1612 (C]N), 1379 (C]N), 1237, 721. 1H-NMR (200
MHz, CDCl3/CD3OD): 0.44 (s, 3H, H3C-18), 0.90 (s, 3H, H3C-19),
1.92 (s, 3H, H3C-21), 1.95 (s, 3H, C(50)-NHCOCH3), 2.00 (s, 3H,
N(30)-COCH3), 2.39 (t, J¼ 9 Hz, 1H, Ha-17), 2.62 (td, J¼ 13.8, 2.2
Hz, 1H, Ha-2), 5.32 (s, 1H, H-4). 13C NMR (50 MHz, CDCl3/
CD3OD): 211.0 (s, C-20), 169.7 (s, C(50)-NHCOCH3), 169.2 (s,
N(30)-COCH3), 145.6 (s, C-50), 144.4 (s, C-5), 120.0 (d, C-4), 79.9
(s, C-3), 63.3 (d, C-17), 55.8 (d, C-14), 53.7 (d, C-9), 43.8 (s, C-13),
38.4 (s, C-10), 36.4 (t, C-12), 35.4 (d, C-8), 34.9 (t, C-1), 31.8 (t, C-
6), 31.4 (q, C-21), 30.9 (t, C-7), 30.7 (t, C-2), 23.9 (t, C-16), 23.0 (q,
COCH3), 22.3 (q, NHCOCH3), 22.0 (t, C-15), 20.7 (t, C-11), 17.1
(q, C-19), 12.8 (q, C-18). ESI-TOF-MS: m/z for C26H37N3O3S [M +
H]+: calcd 472.26284, found 472.26186; m/z for C26H37N3O3S [M
+ Na]+: calcd 494.24478, found 494.24438; m/z for C26H37N3O3S
[M + K]+: calcd 510.21872, found 510.21919.
(3R,17R)-N,N0-(3,300-Diacetyldispiro[[1,3,4]thiadiazoline-2,30-
19-norandrost-4-ene-170,200-[1,3,4]thiadiazoline]-5,500-diyl)bis
[acetamide] (5a). Starting with 420 mg of the mixture of 3a,
elution with toluene/EtOAc/MeOH (50/50/1) and crystallization
from MeOH gave 5a (410 mg, 70%). Rf ¼ 0.24 (CHCl3/MeOH,
95 : 5, double development). Mp. 197.5–202.6 C; [a]D +290 (c
1.0  103 in CH3OH); IR (ATR/cm1): 2939 (C–H), 1642, 1615
(C]N), 1401, 722 (C]S); 1H-NMR (500 MHz, CD3OD): 0.59 (m,
1H, H-9), 0.94 (m, 1H, Ha-7 overlapped with H3C-18), 0.95 (s,
3H, H3C-18), 1.16–1.34 (m, 4H), 1.37–1.50 (m, 2H), 1.68–1.90 (m,
5H), 2.01–2.16 (m, 4H overlapped with two CH3 groups), 2.09 (s,
3H, C(50)-NHCOCH3), 2.12 (s, 3H, C(500)-NHCOCH3), 2.18 (s, 3H,
N(30)-COCH3), 2.22 (s, 3H, N(300)-COCH3), 2.28 (dt, J ¼ 14, 3 Hz,
1H, Hb-6), 2.54 (td, J ¼ 13.5, 3.0 Hz, 1H, Ha-2), 4.35 (dtd, J ¼
13.5, 13.25, 3.0 Hz, 1H, Hb-16), 5.61 (s, 1H, H-4). 13C NMR (125
MHz, CDCl3): 173.5 (s, N(300)-COCH3), 171.9 (s, C(500)-
NHCOCH3), 171.7 (s, C(50)-NHCOCH3), 171.2 (s, N(30)-COCH3),
149.4 (s, C-500), 146.4 (s, C-50), 143.1 (s, C-5), 122.8 (d, C-4), 94.0
(s, C-17), 81.3 (s, C-3), 53.3 (s, C-13), 51.4 (d, C-9), 47.8 (d, C-14),
42.2 (d, C-8), 41.9 (d, C-10), 35.6 (t, C-6), 34.9 (t, C-2), 33.1 (t, C-
12), 32.3 (t, C-7), 31.0 (t, C-16), 27.4 (t, C-11), 27.0 (t, C-1), 25.1 (q,
C(500)-NHCOCH3), 24.3 (t, C-15), 24.0 (q, N(30)-COCH3), 23.1 (q,
N(300)-COCH3), 23.0 (q, C(50)-NHCOCH3), 16.0 (q, C-18). Anal.
calcd for C28H38N6O4S2  2 CH3OH: C 55.36; H 7.12; N 12.91; S
9.85. Found: C 55.64; H 7.32; N 13.31; S 9.63. ESI-TOF-MS: m/z34328 | RSC Adv., 2016, 6, 34312–34333for C28H38N6O4S2 [M + 2H]
2+: calcd 294.12707, found 294.12704;
m/z for C28H38N6O4S2 [M + H]
+: calcd 587.24687, found
587.24700; m/z for C28H38N6O4S2 [M + Na]
+: calcd 609.22882,
found 609.22878.
(3R,17R)-N,N0-(3,300-Diacetyldispiro[[1,3,4]thiadiazoline-2,30-
androst-4-ene-170,200-[1,3,4]thiadiazoline]-5,500-diyl)bis[acetamide]
(5b). Starting with 432 mg of the mixture of 3b, elution with
toluene/EtOAc/MeOH (50/50/1) and crystallization from MeOH
gave 5b (336 mg, 56%). Rf ¼ 0.24 (CHCl3/MeOH, 95 : 5, double
development). Mp. 200.2–202.3 C; [a]D +62 (c 1.02  103 in
CH3OH); IR (ATR/cm
1): 2938 (C–H), 2853, 1665, 1639, 1610
(C]N), 1380, 1254; 1H-NMR (500 MHz, CD3OD): 0.72 (td, J¼ 11,
3.5 Hz, 1H, H-9), 0.91 (m, 1H, Ha-7 overlapped with H3C-18),
0.94 (s, 3H, H3C-18), 1.10 (s, 3H, H3C-19), 1.23 (m, 1H, H-14),
1.31–1.60 (m, 6H, Hb-11, Ha-15, Hb-12, H-8, Hb-1, Ha-11),
1.69–1.90 (m, 4H, Hb-15, Ha-1, Ha-12, Hb-7), 1.98 (d, J ¼ 12.5
Hz, Hb-2), 2.02–2.08 (m, 2H overlapped with two CH3 groups,
Ha-6, Ha-16), 2.09 (s, 3H, C(50)-NHCOCH3), 2.12 (s, 3H, C(500)-
NHCOCH3), 2.18 (s, 3H, N(30)-COCH3), 2.22 (s, 3H, N(300)-
COCH3), 2.78 (td, J ¼ 13.3, 2.5 Hz, 1H, Ha-2), 4.35 (dtd, J ¼ 2.5,
13.25 Hz, 1H, Hb-16), 5.48 (s, 1H, H-4). 13C NMR (125 MHz,
CD3OD): 173.5 (s, N(300)-COCH3), 171.9 (s, C(500)-NHCOCH3),
171.7 (s, C(50)-NHCOCH3), 171.3 (s, N(30)-COCH3), 149.3 (s, C-
500), 147.3 (s, C-5), 146.2 (s, C-50), 121.9 (d, C-4), 93.9 (s, C-17),
81.3 (s, C-3), 55.5 (d, C-9), 53.0 (s, C-13), 48.5 (d, C-14), 38.0 (s,
C-10), 37.6 (d, C-8), 36.7 (t, C-2), 33.4 (t, C-7), 33.1 (t, C-12), 33.0
(t, C-1), 32.9 (t, C-6), 31.0 (t, C-16), 25.1 (q, N(300)-COCH3), 24.4 (t,
C-15), 24.0 (q, N(30)-COCH3), 23.1 (q, C(500)-NHCOCH3), 23.0 (q,
C(50)-NHCOCH3), 21.9 (t, C-11), 18.3 (q, C-19), 15.8 (q, C-18). ESI-
TOF-MS: m/z for C29H40N6O4S2 [M + 2H]
+: calcd 301.13490,
found 301.13535; m/z for C29H40N6O4S2 [M + H]
+: calcd
601.26252, found 601.26266; m/z for C29H40N6O4S2 [M + Na]
+:
calcd 623.24447, found 623.24458.
(3R,17R)-N,N0-(3,300-Diacetyldispiro[[1,3,4]thiadiazoline-2,30-
androsta-4,9(11)-diene-170,200-[1,3,4]thiadiazoline]-5,500-diyl)bis
[acetamide] (5c). Starting with 430 mg of the mixture of 3c,
elution with toluene/EtOAc/MeOH (50/50/1) gave 5c (371 mg,
62%). Rf ¼ 0.19 (CHCl3/MeOH, 95 : 5, double development).
Mp. 199.2–201.1 C; [a]D +178 (c 1.05  103 in CH3OH); IR
(ATR/cm1): 3240, 3071, 2931 (C–H), 1670, 1644, 1613 (C]N),
1378, 1293, 1237, 1030, 724; 1H-NMR (500 MHz, CD3OD): 0.85
(s, 3H, H3C-18), 0.94 (m, 1H, Ha-7), 1.25 (s, 3H, H3C-19), 1.39
(br.q, J ¼ 9.5 Hz, 1H, H-14), 1.53 (m, 1H, Ha-15), 1.78 (m, 1H,
Hb-12), 1.86–1.93 (m, 2H, Ha-1, Hb-15), 1.97 (m, 1H, Hb-7),
2.06–2.16 (4H, Hb-2, Ha-6, H-8, Ha-16, overlapped with two CH3
groups), 2.09 (s, 3H, C(50)-NHCOCH3), 2.12 (s, 3H, C(500)-
NHCOCH3), 2.19 (s, 3H, N(30)-COCH3), 2.23 (s, 3H, N(300)-
COCH3), 2.58 (m, 1H, Ha-12), 2.89 (td, J ¼ 12.5, 5 Hz, 1H, Ha-2),
4.32 (dtd, J¼ 4.0, 13.0 Hz, 1H, Hb-16), 5.46 (d, J¼ 6.0 Hz, 1H, H-
11), 5.48 (s, 1H, H-4). 13C NMR (125 MHz, CD3OD): 173.4 (s,
N(300)-COCH3), 172.0 (s, C(500)-NHCOCH3), 171.9 (s, C(50)-
NHCOCH3), 171.3 (s, N(30)-COCH3), 149.1 (s, C-500), 147.1 (s, C-
9), 146.2 (s, C-50), 146.0 (s, C-5), 122.0 (d, C-4), 118.9 (d, C-11),
93.5 (s, C-17), 81.4 (s, C-3), 51.4 (s, C-13), 46.1 (d, C-14), 40.6
(d, C-10), 39.6 (d, C-8), 35.5 (t, C-12), 34.7 (t, C-1), 33.7 (t, C-7),
33.1 (t, C-6), 32.6 (t, C-2), 31.4 (t, C-16), 26.9 (s, C-19), 25.2 (t,
C-15), 24.9 (q, N(300)-COCH3), 23.9 (q, N(30)-COCH3), 23.0 (q,This journal is © The Royal Society of Chemistry 2016
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View Article OnlineC(500)-NHCOCH3), 22.9 (q, C(50)-NHCOCH3), 15.8 (q, C-18). ESI-
TOF-MS: m/z for C29H38N6O4S2 [M + 2H]
2+: calcd 300.12707,
found 300.12731; m/z for C29H38N6O4S2 [M + H]
+: calcd
599.24687, found 599.24660; m/z for C29H38N6O4S2 [M + Na]
+:
calcd 621.22882, found 621.22859.
(3R,17R)-N,N0-(11a-Acetoxy-3,300-diacetyldispiro[[1,3,4]thia-
diazoline-2,30-androst-4-ene-170,200-[1,3,4]thiadiazoline]-5,500-
diyl)bis[acetamide] (5d). Starting with 450 mg of the mixture of
3d, elution with toluene/EtOAc/MeOH (50/50/0.5) gave 5d (411
mg, 62%). Rf ¼ 0.44 (CHCl3/MeOH, 9 : 1). Mp. 199.2–201.8 C;
[a]D +215 (c 1.03  103 in CHCl3/CH3OH (3 : 1)); IR (ATR/
cm1): 2963 (C–H), 2931, 1703, 1669, 1606 (C]N), 1371, 1240,
1012, 723; 1H-NMR (500 MHz, CDCl3/CD3OD): 1.00 (s, 3H, H3C-
18), 1.02 (m, 1H, Ha-7 overlapped with H3C-18), 1.16 (s, 3H,
H3C-19), 1.26 (t, J ¼ 11.0 Hz, 1H, H-9), 1.34–1.47 (m, 2H, H-14,
Ha-15), 1.55 (dq, J ¼ 3, 11 Hz, 1H, H-8), 1.68–1.87 (m, 5H, Ha-
1, Hb-15, Hb-7, Hb-12, Hb-1), 1.97 (br.d, J ¼ 13.5 Hz, 1H, Hb-2),
2.02 (s, 3H, OCOCH3), 2.11 (s, 3H, C(50)-NHCOCH3), 2.14 (s, 3H,
C(500)-NHCOCH3), 2.19 (s, 3H, N(30)-COCH3), 2.22 (s, 3H, N(300)-
COCH3), 2.80 (td, J ¼ 14, 3 Hz, 1H, Ha-2), 4.37 (dtd, J ¼ 3.5, 13.0
Hz, 1H, Hb-16), 5.16 (br.q, J ¼ 10 Hz, 1H, Hb-11), 5.58 (s, 1H, H-
4). 13C NMR (125 MHz, CDCl3/CD3OD): 171.6 (s, N(300)-COCH3),
170.5 (s, OCOCH3), 169.7 (s, C(50)-NHCOCH3), 169.6 (s, C(500)-
NHCOCH3), 169.2 (s, N(30)-COCH3), 146.7 (s, C-500), 144.3 (s, C-
50), 144.2 (s, C-5), 121.9 (d, C-4), 91.5 (s, C-17), 79.3 (s, C-3), 71.4
(d, C-11), 55.5 (d, C-9), 51.5 (s, C-13), 45.9 (d, C-14), 38.2 (t, C-12),
37.7 (s, C-10), 35.9 (t, C-1), 35.5 (d, C-8), 32.1 (t, C-6), 31.2 (t, C-7),
30.8 (t, C-2), 29.9 (t, C-16), 24.2 (q, N(300)-COCH3), 23.1 (t, C-15),
22.9 (q, N(30)-COCH3), 22.3 (q, C(500)-NHCOCH3), 22.2 (q, C(50)-
NHCOCH3), 21.5 (q, OCOCH3), 17.9 (q, C-19), 15.5 (q, C-18). ESI-
TOF-MS: m/z for C31H42N6O4S2 [M + 2H]
2+: calcd 330.13764,
found 330.13822; m/z for C31H42N6O4S2 [M + H]
+: calcd
659.26800, found 659.26750; m/z for C31H42N6O4S2 [M + Na]
+:
calcd 681.24995, found 681.24989.
(3R,20R/S)-N,N0-(3,300-Diacetyldispiro[[1,3,4]thiadiazoline-
2,30-pregn-4-ene-200,200-[1,3,4]thiadiazoline]-5,500-diyl)bis[acet-
amide] (5e) (R/S). Starting with 460 mg of the mixture of 3e,
elution with CH2Cl2/MeOH (80/20) and crystallization from
CH2Cl2 gave 5e (221mg, 35%) as amixture of two isomers (ratio,
1.2 : 1). Rf ¼ 0.32 (CH2Cl2/MeOH, 20 : 1), Rf ¼ 0.16 (toluene/
EtOAc, 6 : 4, double development). Mp. 191.9–193.2 C; [a]D
+14 (c 0.97  103 in DMSO); IR (ATR/cm1): 3325 (C–H), 2933,
1664, 1644, 1615 (C]N), 1387, 1233. Anal. calcd for
C31H44N6O4S2  CH2Cl2: C 53.85; H 6.50; N 11.77; S 8.97.
Found: C 53.76; H 6.46; N 11.93; S 8.97. ESI-TOF-MS: m/z for
C31H44N6O4S2 [M + 2H]
2+: calcd 315.15055, found 315.15006; m/
z for C31H44N6O4S2 [M + H]
+: calcd 629.29382, found 629.29187;
m/z for C31H44N6O4S2 [M + Na]
+: calcd 651.27577, found
651.27484; m/z for C31H44N6O4S2 [2M + H]
+: calcd 1257.58037,
found 1257.57804.
(5e major). 1H-NMR (500 MHz, DMSO): 0.66 (m, 1H, H-9),
0.80 (m, 1H, Ha-7), 0.85 (s, 3H, H3C-18), 0.94 (m, 1H, H-14),
0.99 (s, 3H, H3C-19), 1.91 (s, 3H, H3C-21), 2.008 (s, 3H, C(50)-
NHCOCH3), 2.013 (s, 3H, C(500)-NHCOCH3), 2.07 (s, 3H, N(300)-
COCH3), 2.09 (s, 3H, N(30)-COCH3), 2.69 (m, 2H, Ha-2, Ha-17
from the minor product), 3.13 (t, J ¼ 8.0 Hz, 1H, Ha-17), 5.40 (s,
1H, H-4), 11.42 (s, 1H, NH), 11.44 (s, 1H, NH). 13C NMR (125This journal is © The Royal Society of Chemistry 2016MHz, DMSO): 169.2 (s, C(50)-NHCOCH3), 169.1 (s, C(500)-
NHCOCH3), 168.2 (s, N(300)-COCH3), 167.3 (s, N(30)-COCH3),
144.6 (s, C-5), 143.4 (s, C-500), 143.1 (s, C-50), 120.7 (d, C-4), 83.8
(s, C-20), 78.8 (s, C-3), 54.9 (d, C-14), 54.1 (d, C-17), 53.6 (d, C-9),
42.0 (s, C-13), 36.6 (t, C-12), 36.3 (s, C-10), 34.8 (t, C-1), 34.4 (d, C-
8), 30.5 (t, C-2), 31.9 (t, C-7), 31.3 (t, C-6), 30.9 (q, C-21), 24.6 (t, C-
16), 24.6 (q, N(300)-COCH3), 23.6 (q, N(30)-COCH3), 23.1 (t, C-11),
22.5 (q, C(500)-NHCOCH3), 22.5 (q, C(50)-NHCOCH3), 20.2 (t, C-
15), 17.3 (q, C-19), 13.0 (q, C-18).
(5e minor). 1H-NMR (500 MHz, DMSO): 0.68 (m, 1H, H-9),
0.73 (s, 3H, H3C-18), 0.80 (m, 1H, Ha-7), 1.01 (s, 3H, H3C-19),
1.05 (m, 1H, H-14, overlapped with H3C-19 signal), 1.94 (s, 3H,
H3C-21), 2.01 (2s, 6H, C(50)-NHCOCH3 and C(500)-NHCOCH3),
2.05 (s, 3H, N(300)-COCH3), 2.09 (s, 3H, N(30)-COCH3), 2.69 (m,
2H, Ha-2, Ha-17), 5.41 (s, 1H, H-4), 11.35 (s, 1H, NH), 11.45 (s,
1H, NH). 13C NMR (125 MHz, DMSO): 169.2 (s, C(500)-
NHCOCH3), 169.2 (s, C(50)-NHCOCH3), 168.1 (s, N(300)-COCH3),
167.3 (s, N(30)-COCH3), 144.6 (s, C-5), 143.5 (s, C-500), 143.1 (s, C-
50), 120.7 (d, C-4), 82.0 (s, C-20), 78.8 (s, C-3), 55.3 (d, C-14), 54.6
(d, C-17), 53.6 (d, C-9), 42.9 (s, C-13), 38.7 (t, C-12), 36.3 (s, C-10),
34.8 (t, C-1), 34.7 (d, C-8), 30.5 (t, C-2), 31.9 (t, C-7), 31.3 (t, C-6),
29.1 (q, C-21), 25.4 (t, C-16), 24.5 (q, N(300)-COCH3), 23.6 (q, N(30)-
COCH3), 23.3 (t, C-11), 22.6 (q, C(500)-NHCOCH3), 22.5 (q, C(50)-
NHCOCH3), 20.4 (t, C-15), 17.3 (q, C-19), 13.3 (q, C-18).Single-crystal X-ray crystallography
Crystals suitable for structural analysis were obtained by slow
recrystallization from DMSO. Single-crystal X-ray diﬀraction
data for 4a were collected at room temperature on an Agilent
Technologies Gemini S diﬀractometer with Mo Ka radiation
(l ¼ 0.71069 A˚). Data collection, unit cell nding, intensity
integration and scaling of the reections were performed with
CrysAlisPro soware.58 An empirical absorption correction using
spherical harmonics, which was implemented in the SCALE3
ABSPACK scaling algorithm within CrysAlisPro, was applied. The
crystal structure was solved by the dual space method using
SHELXT59 and rened using SHELXL-2014 (ref. 59) with
SHELXLE60 as a graphical interface.
All non-hydrogen atoms were rened anisotropically. The
hydrogen atoms that were attached to C atoms were placed at
geometrically idealized positions, with the C–H distances xed
at 0.93 and 0.96 A˚, and their isotropic displacement parameters
were set at equal to 1.2Ueq and 1.5Ueq from sp
2 and sp3 C atoms,
respectively. The orientation of methyl group hydrogens was
rened to best t the observed electron density. The hydrogen
atom that was attached to a nitrogen atom was located in
a diﬀerence Fourier map and rened isotropically. An absolute
structure was assigned to match the known absolute congu-
ration of the steroid molecule.
Inspection of the 3D diﬀerence Fourier map revealed voids in
the crystal structure, which were occupied by disordered solvent
molecules. The total volume of solvent-accessible voids calcu-
lated using PLATON61 was found to be 22.4% of the unit cell
volume. Because the disorder could not be modeled reasonably,
the contribution of the disordered solvent region to the
observed structural factors was removed by the SQUEEZERSC Adv., 2016, 6, 34312–34333 | 34329
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View Article Onlineprocedure62 implemented in PLATON. The estimated number of
electrons in void regions was calculated to be 120 per unit cell,
which corresponds to approximately 3 DMSO molecules per
unit cell. Analytical data on the chemical composition point to 4
DMSO molecules per unit cell.
The nal results of the crystal structure determination are
summarized as follows. Molecular formula: C23H31N3O3S; Mr ¼
429.57; crystal system: tetragonal; space group: I4; unit cell
parameters: a¼ 21.9810(3) A˚, c¼ 10.9904(3) A˚, V¼ 5310.2(2) A˚3;
Z ¼ 8; m ¼ 0.146 mm1; 15 692 reections measured, 6161
unique reections (Rint¼ 0.047); 99.7% data completeness up to
2q ¼ 52.64, 90.3% data completeness up to 2qmax ¼ 58.24;
4874 reections with I > 2s(I); number of rened parameters:
278; R1 ¼ 0.055 for data with I > 2s(I); wR2 ¼ 0.149 for all data;
goodness-of-t S ¼ 1.066; Flack x ¼ 0.05(12) determined by
conventional TWIN/BASF renement;63 Flack x ¼ 0.03(3)
determined using the post-renement Parsons quotient
method64 (1931 quotients); Hoo y ¼ 0.04(3) determined using
2769 Bijvoet pairs (9 outliers)65 using an optimized Student's t-
probability plot (n ¼ 99, corr. coeﬀ. ¼ 0.999).66†
Biology
Cytotoxicity assay. For the evaluation of cytotoxicity, six
human cancer cell lines were used: cervical adenocarcinoma
HeLa, breast carcinoma MDA-MB-453, breast adenocarcinoma
MDA-MB-361, chronic myelogenous leukemia K562, colon
adenocarcinoma LS174, and lung carcinoma A549, and one
normal human cell line, lung broblasts MRC-5. Experiments
were performed according to previously described methods.39
HeLa (2000 cells per well), MDA-MB-453 (3000 cells per well),
MDA-MB-361 (10 000 cells per well), LS174 (7000 cells per well),
A549 (5000 cells per well) and MRC-5 (5000 cells per well) were
seeded into 96-well microtiter plates and 20 h later, aer cell
adhesion, ve diﬀerent concentrations of the tested compounds
were added to the cells. Only nutrient medium was added to the
cells in the control wells. K562 cells (5000 cells per well) were
seeded 2 h before the addition of the compounds. Stock solu-
tions of the compounds, prepared according to a previously
described procedure,37–39 were diluted with complete nutrient
medium and applied to the target cells at various nal
concentrations ranging from 6.25 mM to 100 mM or 12.50 mM to
200 mM. The nal DMSO concentration did not aﬀect cell
viability. Survival of the target cells was determined by an MTT
test aer 72 h of continuous activity of the agents, according to
the method of Mosmann,67 which was modied by Ohno and
Abe68 and used in our previous studies.37–39 Cisplatin was used
as a positive control.
The isolation and treatment of peripheral blood mono-
nuclear cells (PBMC) were carried out according to a previously
reported method.48
Live subject statement
The authors state that all experiments were performed in
compliance with the relevant laws and institutional guidelines.
The cytotoxicity assays using PBMC were approved by the Ethics
Committee of the Institute of Oncology and Radiology of Serbia.34330 | RSC Adv., 2016, 6, 34312–34333Written informed consent was obtained from each healthy
blood donor.
Cell cycle analysis. K562 andHeLa cells were treated with two
concentrations of compounds 2a, 2b, 2c, 2e, 5a and 5d (at values
of IC50 and 2IC50 determined aer treatment for 72 h for each
cell line) for 24 and 48 h. Aer the mentioned incubation times,
the cells were collected, washed and xed in 70% ethanol,
according to standard protocol.39,69,70 Cell cycle distribution data
are presented as Xav  S.D. of three independent experiments.
The statistical signicance of diﬀerences between the control
and treated cell samples was evaluated using one-way repeated-
measures ANOVA with Dunnett's post test. Values of p below
0.05 were considered to be statistically signicant.
Morphological assessment of mode of cell death of HeLa. To
examine the mode of cell death of HeLa induced by compounds
2a, 2b, 2c, 2e, 5a and 5d, morphological analysis was under-
taken, as described elsewhere.39,69
FITC-annexin V/propidium iodide double staining assay.
Determination of human cervical adenocarcinoma HeLa cells in
the early and late stages of apoptosis was performed by ow
cytometry using FITC-annexin V/propidium iodide staining.
FITC-annexin V was a product of BD Biosciences Pharmingen™.
In brief, HeLa cells (200 000 cells per well) were exposed to
concentrations of double IC50 of the tested steroidal compounds
for 24 h. Aer treatment, the cells were harvested, stained with
FITC-annexin V and propidium iodide according to the manu-
facturer's instructions, and analyzed on a FACSCalibur ow
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data are
presented as mean  S.D. of two independent experiments.
Identication of target caspases. To identify the caspases
involved in the apoptotic pathways induced by compounds 2a,
2b, 2c, 2e, 5a and 5d in HeLa cells, the percentages of cells in the
subG1 phase pretreated with caspase inhibitors were deter-
mined, as previously described by Matic´ et al.69 The specic
caspase inhibitors applied at a concentration of 40 mM were: Z-
DEVD-FMK, a caspase-3 inhibitor, Z-IETD-FMK, a caspase-8
inhibitor and Z-LEHD-FMK, a caspase-9 inhibitor. The cas-
pase inhibitors were purchased from R&D Systems (Minneap-
olis, USA). The compounds were applied to HeLa cells at
concentrations that corresponded to double the values of IC50
obtained aer treatment for 72 h.
Endothelial cell tube formation assay. Possible eﬀects of
compounds 2a, 2b, 2c, 2e, 5a and 5d on the inhibition of
angiogenesis in vitrowere examined by the tube formation assay
on a human umbilical vein endothelial EA.hy926 cell line.55 The
assay was performed according to a previously described
procedure.71 In brief, 24-well plates were coated with 200 mL
Corning® Matrigel® basement membrane matrix (Corning cat.
number 356234). Suspensions of EA.hy926 cells (40 000 cells per
400 mL) were plated on top of each Matrigel-coated well. Then,
200 mL complete nutrient medium (Dulbecco's modied Eagle's
medium with high glucose and 4 mM L-glutamine supple-
mented with 10% heat-inactivated FBS and 25 mM HEPES) was
added to the control cell sample, while solutions in nutrient
medium of the tested compounds were added to the other cell
samples. The plates were incubated for 20 h at 37 C in an
atmosphere of 5% CO2 and humidied air. PhotomicrographsThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineof EA.hy926 cells were captured using an inverted phase-
contrast microscope aer treatment for 20 h. In our experi-
ment, the EA.hy926 cells were exposed to low sub-toxic
concentrations of the investigated compounds (concentrations
of IC20 obtained by an MTT test aer treatment that lasted for
24 h): for compound 2a, the applied concentration was 3.5 mM,
for compounds 2b, 2c and 2e the concentration was 10 mM, for
compound 5a the concentration was 4.5 mM and for compound
5d the concentration was 60 mM.
The brine shrimp test. The brine shrimp test was performed
against freshly hatched nauplii of Artemia salina.57 The method
was slightly modied by our team.39 The compounds were dis-
solved in MeOH/CHCl3, then in various amounts (1.0–0.05 mg)
applied to lter paper discs (8 mm diameter) and the solvent
was evaporated. All samples were tested in triplicate. LC50 was
dened as the concentration of compounds that caused the
death of 50% of nauplii.
Antimicrobial activity. Antibacterial activity was evaluated
using four diﬀerent strains of Gram-positive bacteria: Staphy-
lococcus aureus (ATCC 6538), Kocuria rhizophila (ATCC 9341),
Clostridium sporogenes (ATCC 19404), and Bacillus subtilis (ATCC
6633), and four diﬀerent strains of Gram-negative bacteria:
Escherichia coli (ATCC 25922), Salmonella enterica subsp. enter-
ica serovar Enteritidis (ATCC 13076), Proteus hauseri (ATCC
13315) and Pseudomonas aeruginosa (ATCC 9027). Antibacterial
activity was determined by the well diﬀusion method.72 To each
Petri dish (90 mm diameter), 22 mL nutrient agar (HiMedia,
Mumbai, India) and 100 mL bacterial suspension (106 cells per
dish) were added. A well with a diameter of 8 mm was then
punched carefully using a sterile cork borer and 100 mL test
substance (1 mg/100 mL DMSO) was added to each labeled well.
Amikacin (30 mg/100 mL H2O) was used as a positive control,
whereas 100 mL water and DMSO served as negative controls.
The same procedure was repeated for diﬀerent microorgan-
isms. Aer the inoculation of the organisms, compounds and
controls, the plates were incubated for 24 h at 37 C. Zones of
inhibition were recorded in millimeters.
The fungi tested were: Candida albicans (ATCC 10231),
Saccharomyces cerevisiae (ATCC 9763) and Aspergillus brasiliensis
(ATCC 16404). Sabouraud dextrose agar (Torlak, Belgrade, Ser-
bia) was prepared according to the manufacturer's instructions.
Into each sterile Petri dish (90 mm diameter), 22 mL previously
prepared agar suspension was poured and 100 mL fungi (105
spores per dish) was added. A well with a diameter of 8 mm was
punched using a sterile cork borer. Into each well 100 mL test
substance (1 mg/100 mL DMSO) was added. Nystatin (30 mg/100
mL DMSO) was used as a positive control, whereas 100 mL DMSO
served as a negative control. The plates were incubated for 48 h
at 24 C. Antifungal activity was determined by measuring the
diameter of the inhibition zone.Conclusions
In this study, a series of new steroidal mono- and bis(thiose-
micarbazones) 2a–e and 3a–e were prepared and further sub-
jected to ring closure by means of acetylating agents to aﬀordThis journal is © The Royal Society of Chemistry 2016the corresponding 1,3,4-thiadiazolines 4a–e and 5a–e in good
yields.
All compounds were biologically evaluated. The results of
our in vitro study may indicate the signicant anticancer
potential of steroidal compounds 2a, 2b, 2c, 2e, 5a and 5d,
owing to their strong antiproliferative and pro-apoptotic eﬀects
against malignant cell lines and the specicity to cancer cells of
their activity. Among these novel steroid derivatives, the best
anticancer properties were exhibited by compound 5a. The
spiro heterocyclic substituent at the C-17 position, as well as the
presence of an a,b-unsaturated thiosemicarbazone moiety at C-
3, enhanced the activity of the tested compounds. Moreover,
their low antimicrobial activities indicate the selective activity of
these new substituted and heterocyclic steroid derivatives.
Further research is needed to investigate the molecular
mechanisms of their anticancer activity, in addition to in vivo
evaluation of their antitumor eﬃcacy.Acknowledgements
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